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Abstract 
Diabetes mellitus type 2 is a severe metabolic disorder which is defined by development of insulin 
resistance and decreased insulin secretion due to a progressive loss of β-cells. The loss of β-cells 
can be preceded by mitochondrial dysfunction, but so far the event leading to mitochondrial 
dysfunction has yet to be elucidated. MicroRNAs are small non-coding RNA molecules that 
regulate gene expression post-transcriptionally by binding directly to the mRNA molecule, 
microRNAs have been found in the mitochondria and may be a cause of the mitochondrial 
dysfunction. The purpose of this thesis was to try to predict microRNA target sites within the 
mitochondrial genes with an in silico approach. Four target sites for miR-29a, miR-125a, miR-152 
and miR-223 were found and tested with a reporter gene assay. However no regulation on the 
target sites could be measured, except for miR-223 where a cryptic target site in the reporter gene 
interfered with the result. miR-125a, miR-152 and miR-223 were also tested for their effect on the 
mitochondria, the measured parameters were glucose stimulated insulin secretion (GSIS), which is 
closely linked to mitochondrial function, and mitochondrial mass, membrane potential and 
superoxide production. MiR-125a showed no effect on any of the measured parameters, miR-152 
and miR-223 increased GSIS, and miR-223 also increased mitochondrial mass and superoxide 
production. Indicating that miR-223 regulates the mitochondria, although the exact mechanism 
remains unknown. A limitation of current reporter gene assays is that they are designed to work in 
the cytosolic compartment and not the mitochondria environment. Therefore a reporter gene 
assay selective for the mitochondrial compartment, based on mitochondrial tRNA codon 
deviations were constructed and tested. The assay suffered from low expression of the reporter 
gene, and selective expression in the mitochondrial compartment could not be confirmed, so 
further refinements and controls are needed before it can be used for its intended purpose. 
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Dansk Resume 
Diabetes mellitus type 2 er en alvorlig lidelse som er defineret ved udviklingen af insulin resistens 
og tab af β-celler med nedsat insulin sekretion til følge. Tabet af β-celler kan forudgåes af 
mitokondriel dysfunktion, men indtil videre er hændelses forløbet der medfører mitokondriel 
dysfunktion ikke beskrevet. MicroRNAs er små ikke kodende RNA molekyler, der post-
transkriptionelt regulerer gen ekspression ved at binde sig direkte til mRNA molekylet. MicroRNA 
er blevet lokaliseret i mitokondriet og kan muligvis være årsagen til den mitokondriel dysfunktion. 
Formålet med dette speciale var at forsøge at prøve at bestemme potentielle microRNA 
bindingsteder i de mitokondrielle gener in silico. Fire bindingsteder for miR-29a, miR-125a, miR-
152 og miR-223 blev fundet og testet med et reporter gen assay. Der kunne ikke påvises regulering 
af bindingstederne, undtagen for miR-223 hvor et alternativt bindingsted blev fundet i selve 
reportergenet, hvilket påvirkede resultatet. miR-125a, miR-152 og miR-223 blev også testet for 
deres effekt på mitokondriet, de målte parameter er glukose stimuleret insulin sekretion (GSIS), 
som er tæt knyttet til mitokondriel funktion, og mitokondriel masse, membran potentiale og 
superoxid produktion. Mir-125a udviste ingen effekt på de målte parameter, miR-152 og miR-223 
øgede GSIS og miR-223 øgede også den mitokondrielle masse og superoxid produktion. Hvilket 
indikerer at miR-223 regulerer mitokondriet om end den eksakte mekanisme er ukendt. En 
begrænsning ved nuværende reporter gen assays er at de er designet til at virke i cytosolen og ikke 
i mitokondriet. Derfor blev et reporter gen assay selektiv for mitokondriet, baseret på 
mitokondriel tRNA kodon forskelle, konstrueret og testet. Assayet havde lav ekspression af 
reporter genet og selektiv udtryk i mitokondriet kunne ikke bekræftes, so yderligere forbedringer 
og kontroller er nødvendige for assayet eventuelt kan anvendes.  
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1 Introduction 
Diabetes mellitus (DM) is a diverse subset of non-communicable metabolic disorders. DM differs in 
their underlying pathology, but share common symptoms. Currently 9% of the world’s adult 
population suffer from DM and causes 1.5 million deaths annually. DM is unfortunately incurable 
and the expenses to lifelong treatment and co-morbidities pose a severe socio-economic burden. 
 
The term "diabetes mellitus" describes a metabolic disorder of multiple aetiology characterized by 
chronic hyperglycemia with disturbances of carbohydrate, fat and protein metabolism resulting 
from defects in insulin secretion, insulin action, or both. The effects of diabetes mellitus include 
long–term damage, dysfunction and failure of various organs (WHO 2006)1. 
 
DM was historically divided into type 1 and 2 depending on whether treatment required insulin or 
not. Today it is known that the underlying causes of DM are very broad and there are several 
different subtypes of diabetes depending on their pathology, but the original terminology persists. 
In this study the focus will be on Diabetes mellitus type 2 (T2DM). T2DM is characterized as a 
condition where progressive loss of insulin sensitivity and β-cells cause both the amount and 
effect of insulin to become insufficient to maintain a normal glucose homeostasis. T2DM is by far 
the most common type of diabetes, but it was previously a disease that primarily affected the 
elderly. Modern sedentary lifestyle and excessive calorie intake has increased both the incidence 
and prevalence in the general population1. The loss of β-cells in DMT2 has been observed to be 
preceded by mitochondrial dysfunction, but so far the event leading to mitochondrial dysfunction 
has yet to be elucidated. Recent findings of both microRNA and subunits of the RNA induced 
silencing complex in the mitochondria present a possible cause for mitochondrial dysfunction. 
Currently little published material regarding miRNA and intra-mitochondrial effects are available, 
the purpose of this thesis will therefore be to predict potential microRNAs that may act within the 
mitochondria, validate the interaction and determine potential mitochondrial phenotypes. 
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1.1 Thesis outline 
The thesis is divided into several sections; the remaining part of section 1, the introduction, will 
provide the theoretical framework for this thesis regarding the current understanding of the 
development of T2DM, microRNA and their functions, as well as a description of the mitochondrial 
gene expression. Section 2 provides the aim of the study, which has been subdivided into three 
experiments; in silico detection of mitochondrial miRNA target sites, mitochondrial dependent 
phenotypes derived from miRNA over expression and the development of a mitochondria 
selective reporter gene assay. Section 3 is subdivided for the three experiments and a brief 
overview of the methodology. Section 4 presents the results obtained from the methods used in 
section 3. Section 5 contains the discussion were the results are interpreted. Section 6 and 7 is the 
conclusion and perspectives. Section 8 contains the full list of references used, listed in the 
Vancouver format. The appendix contains specific protocols used for selected methods, as well as 
some results omitted from the report.  
 
1.2 Diabetes mellitus type 2 
In healthy individuals the glucose homeostasis is maintained primarily by the two antagonistic 
hormones insulin and glucagon. Insulin lowers plasma glucose by promoting glucose uptake from 
the target tissue (e.g. muscle, liver, fat), whereas glucagon promotes glucose release from the 
liver. In the fed state blood glucose is increased and the ratio of insulin to glucagon will favor 
insulin, and the fasting state when glucose is decreased will favor glucagon (Figure 1)2. In T2DM 
the insulin secretion is impaired and the glucose homeostasis cannot be maintained. The primary 
initiator in the development of T2DM is low response to insulin in the peripheral tissue, commonly 
known as insulin resistance (IR), and often linked to obesity1. TDM2 susceptible individuals have an 
underlying polygenetic disorder which causes defects in the β-cell compensatory mechanisms, 
preventing sustained compensation to the increased insulin demands3. The compensatory 
insufficiency caused the β-cells to become dysfunctional and eventually die from apoptosis in their 
effort to cope. The loss of β-cells is irreversible due to the limited proliferatory potential of β-cells 
and the burden on the remaining β-cells is increased causing, a viscous circle of progressive loss of 
β-cell mass and T2DM develops. The insulin insufficiency causes chronic hyperglycemia which 
damages sensitive tissues, and in the long-term leads to severe secondary condition and even 
death1,4. 
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Figure 1 - Glucose homeostasis: Schematic view of glucose homeostasis as maintained by insulin and glucagon. At 
high blood glucose levels the β-cells is stimulated to secrete the hormone insulin. Insulin promotes glucose uptake in 
the muscle, liver and adipose tissue. When blood glucose becomes low α-cells is stimulated to secrete the hormone 
glucagon. Glucagon causes glucose to be secreted to the blood from mobilized glycogen reserves in the liver.  (Picture 
obtained from 5) 
 
1.2.1 Metabolic syndrome 
Before T2DM manifest itself, it is almost always preceded by the metabolic syndrome (MS)1,4. MS 
is a combination of risk factors which can be measured non-invasively and empirically has been 
shown to be associated with increased risk of cardiovascular diseases, stroke and T2DM. The 
parameters varies between different organizational bodies, basically encompass the four medical 
conditions: abdominal obesity, dyslipidemia, elevated blood pressure and increased fasting 
glucose. The parameters can be thought as a collection of biomarkers that measures underlying 
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disorders of nutrient storage and utilization6. For susceptible patients T2DM, MS is the last stage 
where the β-cell mass is large enough to prevent or delay T2DM4. However as the β-cell failure 
cannot be treated directly, the current prevention strategies are primarily aimed at decreasing the 
acquired insulin resistance6 through “intensive” lifestyle interventions aimed at weight loss and 
exercise7. 
 
1.2.2 Insulin resistance 
In relation to glucose homeostasis insulin has three primary target tissues; liver, muscles and 
adipocyttes. The common action of insulin is the binding to membrane insulin receptor tyrosine 
kinases (INR) binding leads to the phosphorylation of insulin receptor substrate (IRS) 1 and 2. 
IRS1/2 in turn leads activation of protein kinase 2 (AKT2) via phosphoinositide 3-kinase and 3-
phosphoinositide-dependent protein kinase 1 (PDK1). AKT2 increase glycogen synthesis and 
inhibits of gluconeogenesis in the liver. This lowers the amount of glucose produced and binds 
plasma glucose in the liver cells as glycogen8. In the skeletal muscle Akt2 leads to glucose 
translocater 4 (GLUT4) containing vesicles to fuse with the membrane, GLUT4 then allows glucose 
entry to the cell, which can be bound as glycogen. In adipocyttes AKT2 activation leads to GLUT4 
translocation as well, while decreasing lipolysis, and increasing lipogenesis9. Together these effects 
help to decrease the plasma glucose levels. IR develops when the amount of circulating 
triacylglycerid (TAG) and free fatty acids (FFA) surpasses the adipose tissue capabilities and 
accumulates in ectopic tissue such as the liver and skeletal muscle. The accumulation of lipids in 
these tissues is believed to cause an increase in the metabolites diacylglycerol (DAG)10,11 and 
ceramide12. DAG and ceramide both act as secondary messengers within the cell and interferes 
with intracellular insulin signal transduction. DAG activates protein kinase C (PKC), c-Jun terminal 
kinases (JNK) and inhibitor of nuclear factor kappa B kinase beta (IKKβ). PKC inhibits the INR and 
IRS, JNK and IKKβ inhibits IRS. The ceramides activate protein phosphatase 2a (PP2a), which 
dephosphorylates Akt2 (Figure 2). The consequence is impaired insulin effect and increased 
amount of insulin is needed for the same results. The central role of TAG and FFA helps to show 
the correlation between obesity and IR development, and why therapeutic regiments aimed at 
weight loss during MS can prevent diabetes4,7. 
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Figure 2 – Model of Insulin resistance development: When exceeds free fatty acid (FFA) enters the cell, diacylglycerol 
(DAG) and ceramide increases. DAG inhibits insulin signaling at the insulin receptor level, whereas ceramide inhibits 
the downstream target protein kinase B. (PKB/AKT). The effect is decreased insulin response. C-Jun N-terminal kinase 
(JNK), protein kinase C (PKC), inhibitor of nuclear factor kappa B kinase beta (IKKβ), phosphatidylinositol-3 
kinase(PI3K), triacylglycerols (TAG), long-chain acyl-CoA (LCA-CoA), nuclear factor kappa B (NFκB), insulin receptor 
substrate (IRS), Phosphatidylinositol 4,5-bisphosphate (PIP2), Phosphatidylinositol (3,4,5)-trisphosphate (PIP3), 
Phosphoinositide-dependent kinase-1 (PDK1), Glucose translocator 4 (GLUT4) and fatty acid transport protein(FATP). 
(Picture adapted from 13) 
 
1.2.3 Normal β-cell function 
Insulin secretion from β-cells is biphasic and principally regulated by the plasma glucose levels. 
However glucose does not directly initiate insulin secretion, but does so through mitochondrial 
metabolites, making the mitochondrial function essential for insulin secretion14. Plasma glucose is 
continuously equilibrated with the β-cell cytosol via a constitutively active GLUT. Inside the β-cells 
the glucose is converted to pyruvate via glycolysis. The pyruvate is shuttled into the mitochondria 
where it produces ATP from ADP via the citric acid cycle (TCA). The generation of ATP elevates the 
ATP to ADP ratio and closes ATP-sensitive potassium channel (KATP channel). The net result of the 
closing of the KATP channel is a depolarization of the cell and Ca
2+ influx from the voltage 
dependent calcium channels (VDCC). The Ca2+ is the main signal that drives the secretion of insulin 
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from immediately releasable insulin vesicles; this is known as 1st phase insulin release15,16. After 
the initial high 1st phase insulin release, a lower 2nd phase insulin release is maintained from the 
delayed mobilization of insulin reserve vesicles to the ready releasable pool. The process regarding 
the release of the reserve pools is maintained from increased Ca2+ levels independent of the KATP 
channel16. The mitochondrial derived metabolites; malate, citrate, isocitrate, phosphoenol 
puryvate, GTP and glutamate are believed to sustain the 2nd phase insulin release by priming new 
vesicles and maintain high Ca2+ levels. Malate, Citrate, Isocitrate are shuttled across the 
mitochondrial membrane where they are oxidized to produce NADPH. Citrate is also a precursor in 
Malonyl-COA and Long-chain-acyl-COA synthesis. The NADPH, GTP, Malonyl-COA, Long-chain-acyl-
COA, glutamate and phosphoenol pyruvate is thought to sustain the 2nd phase insulin release with 
NADPH as the primary consensus factor14 (Figure 3). The glucose stimulated insulin secretion 
(GSIS) is therefore dependent on mitochondrial function, as the mitochondria relays information 
of glucose levels and drive both phases of the insulin secretion.  
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Figure 3 – 2
nd
 phase insulin release:  Regulation of glucose-stimulated insulin secretion by nutrients, hormones and 
neurotransmitters. Glucose-stimulated insulin secretion may be modulated by several mechanisms. Glucose 
metabolism increase ATP/ADP ratio and closes ATP-sensitive potassium channels (KATP), depolarizing the membrane, 
opening voltage-dependent calcium channels (VDCC), and thus increasing intracellular calcium (Ca
2+
). Glucose 
metabolism by the Krebs Cycle also renders a series of metabolic coupling factors that may initiate and sustain insulin 
secretion. These metabolic coupling factors participate in mitochondrial shuttles, involving NADPH, pyruvate, malate, 
citrate, isocitrate, acyl-CoAs, and glutamate. Signaling pathways that contribute to maintaining or increasing glucose-
stimulated insulin secretion include PKA and PKC. Glucagon, glucagon-Like peptide 1 (GLP-1), and glucose-dependent 
insulinotropic peptide (GIP) act through PKA pathway, while acetylcholine and cholecystokinine act through the PKC 
pathway. Fatty acids may contribute to insulin secretion through the PKC pathway through formation of diacylglycerol 
(DAG) or through protein acylation. Aminoacids may stimulate insulin release by increasing ATP production from the 
Krebs Cycle, by membrane depolarization, or by participating in intracellular calcium increase. (αKG: alpha-
ketoglutarate, ACC: Acetyl CoA Carboxylase, FAS: Fatty Acid Synthase, GDH: Glutamate Dehydrogenase, GTP-SCS: GTP-
Succinyl CoA Synthetase, ER: endoplasmic Reticulum, ME: Malic enzyme, MDH: Malate dehydrogenase, PC: Pyruvate 
Carboxylase, PHD: Pyruvate Dehydrogenase, PIP2: Phosphatidyl Inositol Biphosphante, IP3: inositol 1,4,5-
trisphosphate ). (Picture and legend reprinted from 
17
)  
 
The Evidence for the importance of mitochondria for normal β-cell function can be seen from the 
monogenic form of diabetes known as Maternally Inherited Diabetes and Deafness (MIDD) This 
form of diabetes is linked mutations in the mitochondrial genome, and affects the β-cell function 
and insulin secretion. The most common cause of MIDD is a single A3243G substitution in the 
mitochondrial gene encoding tRNAleu18. MIDD causes progressively worsening of the β-cell insulin 
secretion and eventually T2DM in most cases19. 
 
1.2.4 Impaired β-cell function 
When insulin resistance develops the amount of insulin needed to reach normoglycemia increases. 
The compensatory processes primarily include hypertrophy with enhanced insulin biosynthesis as 
human β-cell has a limited capability for proliferation20. In T2DM patients β-cells are defect in the 
compensatory pathways and adequate insulin secretion cannot be maintained, especially 1st phase 
insulin release is lost early, even before T2DM debut and can be used as a prognostic marker21. 
The stress on the T2DM β-cells eventually leads to dysfunction and apoptosis and the irreversible 
loss of β-cells accelerates the hyperglycemia and severity of the disease22. Due to the polygenetic 
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nature of T2DM several possibly defects in the compensatory pathway are known and they include 
but are not limited to; Gluco- and lipotoxicity, Endoplasmatic reticulum (ER) stress and 
mitochondrial dysfunction. Gluco- and lipotoxicity is closely linked and it is known that chronic 
exposure to high glucose and/or fatty acids can lead to mitochondrial dysfunctions of the β-cell 
and apoptosis23. ER stress is caused by the high demand for insulin, which increases the amount of 
unfolded or misfolded proteins in the ER lumen. The presence of unfolded and misfolded proteins 
activates the unfolded protein response, which activates apoptosis via the intrinsic pathway if the 
stress cannot be relieved24. Mitochondria and their dysfunction are especially worth mentioning 
due to their link to both 1st and 2nd phase insulin release, as well as their central role in apoptosis 
via the intrinsic pathway. Furthermore mitochondrial dysfunction and morphogenic changes have 
been observed to precede T2DM in human islets25 as well as at least one mouse model26. The 
specific events of mitochondrial dysfunction are however still debated. Glucose mediated hyper 
polarization of the mitochondrial membrane cause an increase production of radical oxygen 
species (ROS), especially superoxide (O2
-)27. Some evidence points to T2DM patients relieve the 
hyperpolarized state by activation of the uncoupling protein 2 (UCP2). UCP2 causes temporary 
proton leak from the mitochondria and relieves hyperpolarized membrane potential at the cost of 
decreased ATP production, and impaired 1st phase insulin secretion25,28. Loss and Impairment of 1st 
phase insulin secretion one of the earliest signs of β-cell dysfunction21, further supporting the role 
of mitochondria in the first step of T2DM pathogenesis. However the β-cell UCP2 expression levels 
is not believed to be sufficient to relieve the mitochondrial membrane potential to the extend 
observed in vivo29,30. Other sources for mitochondrial dysfunction therefore likely exist; one 
possibility is the small interfering RNA molecules known as microRNA. 
 
1.3 MicroRNA 
MiRNA are a special type of RNA molecules from the family of non-coding RNA (ncRNA) of less 
than 30 nucleotides(nt) in length. miRNA are closely related to the similar short interfering RNA 
(siRNA), but there are key differences; SiRNA are highly gene specific and mediates mRNA cleavage 
and strong transcriptional suppression, miRNAs on the other hand rarely induce mRNA cleavage, 
but usually has multiple targets where the miRNA inhibits translation and increases mRNA 
turnover31. MiRNA plays a key role in regulating fundamental cellular processes, especially in 
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response to changes in the environment by fine tuning gene expression at the transcriptional 
level. The first miRNA were described in C. elegans in 1993 by Lee RC, Feinbaum RL and Ambros 
V32. It was shown that the gene lin-4 did not produce a protein product, but lowered the 
expression of the protein lin-14 – they proposed this to be an effect of the lin-4 RNA interacting 
with the lin-14 RNA. In 2001 it was recognized that miRNA induced gene regulation was an ancient 
and conserved mechanism with homologs in mammals33,34 eq. lin-4 mammalian homolog is miR-
125. The amount of published articles has been steadily increasing with 24621 articles in 2015 
according to the pubmed databasea. Today 258835 miRNA are known and conserved miRNA 
binding sites are found in over 60% of the human protein encoding genes36. 
 
1.3.1 MiRNA biogenesis 
The biogenesis for miRNA has some non-canonical pathways37, but the canonical pathway for 
mammalian miRNA biogenesis can be seen in Figure 4 - A. The first step is the transcription of the 
primary miRNA (pri-miRNA) transcript by RNA polymerase II. The pri-miRNA contains a 
characteristic hairpin loop, where the functional miRNA sequence is embedded. The hairpin 
structure is recognized and bound by Drosha and DGCR8/Pasha which form a complex with the 
hairpin known as the microprocessor. The microprocessor cleaves the pri-miRNA in defined 
positions between the region residing ~11bp from the base of the stem and ~22bp below the start 
of loop creating a ~22bp double stranded RNA molecule with a 2 nucleotide overhang at the 3’ 
end see Figure 4 - B. The pre-miRNA is recognized and bound by Exportin 5 via the stemloop and 
the 2 nucleotide (nt) overhang and translocated the pre-miRNA to the cytosol. In the cytosol the 
pre-miRNA is recognized by its terminal loop and bound by Dicer. Dicer then cleaves the miRNA at 
~21-25 nt from the 3’ end and/or 22 nt from the 5’ of the basal end of the pre-miRNA, see Figure 4 
- C. The RNA-RNA duplex is subsequently bound by one of 4 Argonaute (AGO) subunits of the RNA 
induced silencing complex (RISC). The orientation of the strands during loading is dependent on 
several factors, especially the thermodynamic bias of the 2 ends of the duplex and the 5’ 
nucleotide. This means there is a bias for one strand to make a complex with AGO protein and 
become a mature miRNA and a guide strand for the RNA induced silencing complex (RISC). The 
other strand, named the passenger strand, is unwound and degraded. The strand selection 
                                                     
a
According to the Pubmed database containing “microRNA” in either title or abstract. 
Located on [18.01.2015]: http://www.ncbi.nlm.nih.gov/pubmed/ 
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process is not completely strict, and both strands will be able to form complex with AGO albeit in 
various proportions31,38,39.  
 
 
Figure 4 - miRNA biogenesis: The pri-miRNA is transcribed from DNA and process by Drosha /Pasha complex to the 
pre-miRNA. Exportin 5 translocates the pre-miRNA to the cytosol where the loop is cleaved off. One RNA strand is 
incorporated into the RISC complex. (Picture reprinted from 31) 
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Figure 5 – Specific cleavage site for the microprocessor and Dicer: A: Drosha cleaves the pri-miRNA between the 
lower and upper stem, corresponding to ~11bp from the start of the stem to ~22bp from the start of the loop. B: Dicer 
cleaves the pre-miRNA 22 nt from the 5’, and 21-25nt from the 3’ end with its RNase III domain (RIIID) a and b. 
(Picture adapted from 38) 
 
1.3.2 miRNA structure  
Most miRNA are ~20-25 nucleotides long and can be divided into different regions in respect to 
AGO driven gene suppression. The specificity of mRNAs regulated by a given miRNA is dependent 
on the seed region. The seed region is from the second nucleotide to the eight of the miRNA. In 
most cases a perfect six nucleotide stretch is necessary, although bulges and mismatches have 
been observed40. In AGO the seed region is exposed within the MID domain of the AGO protein 
and used to scan mRNA for a complimentary site. The very first nucleotide is bound by 5’ 
nucleobase binding region of the AGO protein and does not participate in the mRNA scanning. The 
base-pairing between nucleotide nine to twelve of the guide strand and the mRNA is rarely seen in 
miRNA, but important for gene silencing with siRNA as a perfect match are required to activate 
AGO2’s intrinsic RNA activity.  Nucleotide thirteen to sixteen increase suppression. The remaining 
3’ nucleotides can have beneficial effect on the thermodynamically interaction between the two 
RNA strands in regards to relieving secondary structures. 
 
Figure 6 – miRNA functional regions: Region 1 - Nucleotide 2-8 (red): defines seed region and defines mRNA matches. 
Region 2 - nucleotide 9-12 (blue): Perfect base pairing in this region is necessary for argonaute mediated RNA 
cleavage. Region 3 – nucleotide 13-16 (green): Base pairing in this region increase repression by the RNA induced 
silencing complex. Region 4 – nucleotide 17-end (black): Base pairing in this region increase the thermodynamically 
stability of the complex. 
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1.3.3 MiRNA driven repression 
The canonical effect of miRNA is repression mediated by the miRNA loaded RISC (miRISC) when 
bound to the 3’ UTR of the mRNA. The repression is achieved in two ways, by inhibiting ribosomal 
translation and increasing the mRNA degradation rate (Figure 7). Upon successful binding of the 
miRISC to the target mRNA the scaffold protein GW182 is recruited. GW182 interacts with 
cytoplamisc poly(A)-binding protein (PABPC) and the two poly(A) specific ribonuclease subunits 
(PAN) 2 and 3. GW182 also interact with the Chemokine (C-C Motif) Receptor 4 (CCR4) and 
Negative Regulator Of Transcription (NOT) CCR4–NOT complex. The PAN2–PAN3/CCR4–NOT 
complexes remove the protective poly(A) tail from the mRNA target. Dead box protein 6 (DDX6) 
binds to NOT1 and recruits the decapping complex consisting of enhancer of decapping (EDC) 3 
and 4, and decapping protein (DCP) 1 and 2. Decapping of the transcript prevents ribosomal access 
and together with deadenylation targets the mRNA for degradation by exoribonuclease 1 (ERI1). 
The miRISC is also believed to interfere with the eukaryotic initiation factor 4F (eIF4) complex. The 
eIF4F complex is essential for pre-initiation complex and for translation initiation, but the exact 
molecular mechanism is not elucidated41 (Figure 7). An interesting observation made is miRNA 
inside the mitochondrial compartment as well as the AGO2 protein42 these findings opens the 
question for possible miRNA mediated regulation of translation inside the mitochondria. 
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Figure 7 – Canonical miRNA mediated repression and mRNA decay: The figure depicts the proteins interacting in 
miRNA mediated repression and decay of mRNA transcripts, upon binding of the miRNA loaded RNA induced silencing 
complex (miRISC).  GW182 acts as a scaffold and recruits the poly(A) specific ribonuclease (PAN) subunits 2 and 3, 
which deadenylates the poly(A) tail together with the Chemokine (C-C Motif) Receptor 4 (CCR4) and Negative 
Regulator Of Transcription (NOT) CCR4–NOT complex. Dead box protein (DDX6) has binding site to both NOT1 and 
enhancer of decapping (EDC) subunit 3, and is believed to recruit the EDC and decapping protein (DCP) complex, 
which mediates decapping of the mRNA. Exoribonuclease 1 (not shown) mediates 5’ to 3’ degradation. Translational 
initiation is also inhibited by an unknown interaction with eukaryotic initiation factors 4 (eIF4) complex. (Picture 
adapted from 41).  
 
1.4  The Mitochondria 
The mitochondria are an important organelle found in almost every cell of the body and are 
considered the powerhouse of the cell, as they are the primary source of energy in the form of 
ATP produced from oxidative phosphorylation. According to the endosymbiotic theory the 
mitochondria originated from an endosymbiotic bacteria, which subsequently lost its genetic 
autonomy to its host cell. The basis for endosymbiotic theory is evident from the fact that the 
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mitochondria contains their own small 16,569bpb circular genome, containing only 37 genes and 
one regulatory region, the D-loop. The remaining mitochondrial proteins are encoded in the 
nucleus and mitochondrial biosynthesis is under nuclear control43. 
 
1.4.1 Mitochondrion structure and function 
The mitochondria have two membranes; the outer and inner membrane. The outer membrane 
has transmembrane proteins named porins, which form pores and allows free passage of small 
molecules of 6-10kDa and less (ATP, glucose, NADPH etc.). The inner membrane is folded in cristae 
and impermeable for most molecules. Transport across the membranes is therefore facilitated by 
mitochondrial translocators, The electron transport chain and ATP synthases are embedded in the 
inner membrane and is the site of oxidative phosphorylation. The intermembrane space of the 
inner membrane is known as the matrix and it contains solubilised intermediates and enzymes of 
the TCA, as well as several copies of the mitochondrial DNA, mRNA and ribosomes43 (Figure 8). 
The impermeable nature of the of the mitochondrial membranes, as well as different 
concentrations of the mitomiRs means that the miRNA speculated to be moved across the 
membranes by an active process possibly involving mitochondrial translocators42.  
 
Figure 8 – Simplified overview of 
mitochondrial structure: The 
outer membrane contains porins 
which forms pores. The inner 
membrane is folded in structures 
known as cristae, the cristae 
contains the electron transport 
chain and ATP synthase.  The 
matrix contains several copies of 
the mitochondrial genome, the 
citric acid cycle enzymes and 
intermediates, ribosomes and 
tRNAs. (Figure adapted from 44) 
 
                                                     
b
 The size varies between species, this is the size for the homo sapiens mitochondrial genome. 
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1.4.2 Mitochondrial genes and their translation 
The mitochondrial genome encodes 13 proteins, 2 ribosomal RNA (rRNA) and 22 transfer RNAs 
(tRNA), and deviates considerably from normal eukaryotic transcription and translation. The 
genome is transcribed from both strands from designated promoter, forming polycistronic 
transcripts. One strand is designated the heavy strand (H-strand) and the other the light strand (L-
strand). The H-strand encodes 12 proteins, two rRNAs and 14 tRNAs, the L-strand encodes one 
protein and eight tRNAs. The genes are tightly packed on the genome without introns and are only 
separated by a few bp, or may even be overlapping43 (Figure 9). 
 
Figure 9 – Mitochondrial genome: The 37 mitochondrial genes consist of 13 proteins, as well as the 2 rRNA and 22 
tRNA. The tRNA (TRN*) is interspaced between almost all genes. CR is the control region containing the 
mitochondrial promoters and is also known as the D-loop. (Picture adapted from 44) 
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Transcription is initiated from the heavy- or light-strand promoter within the D-loop by the 
mitochondrial RNA polymerase (mtRNAP) together with the Mitochondrial transcription factor A 
(TFAM) and either the mitochondrial transcription factor 1 or 2 (TFB1M and TFB2M)45,46. The H-
strand and L-strand are then transcribed as one long polycistronic transcripts, meaning that same 
strand genes are transcribed in equal proportions. The only exception is the two rRNAs which are 
transcribed as the first genes after the promoter and directly and have a mitochondrial 
transcription termination sequence immediately after the second rRNA47,48. The protein encoding 
genes are in most cases flanked by tRNAs meaning that monogenic mRNAs is generated when the 
tRNA are processed and excised from the primary polycistronic transcript. The mRNA transcripts 
not interspaced by tRNA is believed to contain a secondary structure resembling the tRNA 
cloverleaf which mediate restriction enzyme recruitment49. A poly(A) tail is added to the mRNA by 
the mitochondrial poly(A) polymerase after excision50. The lack of regulators for the individual 
genes in mitochondrial transcription means that the genes almost certainly must be regulated 
post-transcriptionally, possibly by miRNAs interactions. 
The mitochondrial translation also resembles prokaryotic translation closer than eukaryotic 
translation, but the mitochondrial translation is still poorly understood, as mitochondrial 
translation from mitochondrial extracts has not yet been successful51,52. The full extent of nuclear 
encoded auxiliary proteins involved in translation is therefore unknown. The current 
understanding of the mitochondrial mediated translation is therefore to some extend inferred 
from observation about the bacterial homologs of mitochondrial protein, and not from 
mitochondrial observations. A more detailed description of the current model of mitochondrial 
translation is depicted in Figure 10.  
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Figure 10 – mitochondrial translation: Initiation: The mitochondrial initiation factor 3(mtIF3) binds to rRNA 28S, and 
moves it to the startcodon. mtIF2 insert the initiation tRNA into the peptidyl (P) site. mtIF2 and 3 and then released by 
rRNA 39S binding
53
. Elongation: The GTP-binding mitochondrial elongation factor TU (mtEFTu) binds loaded tRNAs, 
and moves them in the acceptor (A) site. The amino acid is added to the peptide chain, and the ribosome moves and 
releases the empty tRNA in the P site
54
. Termination: The mitochondrial release factor 1 and 1a (mtRF1/mtRF1a) 
releases the protein from the ribosome. Mitochondrial ribosome recycling factor (mtRRF) and mitochondrial 
elongation factor G 2 (mtEFG2) disassociate the ribosome and releases the mRNA
55
. (Picture reprinted from 51) 
 
1.4.3 MiRNA and mitochondrial regulation 
Many details of mitochondrial translation are poorly understood, and the identification of miRNA 
inside the mitochondria as well as the AGO2 protein42,56 opens the question for possible miRNA 
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mediated regulation of translation inside the mitochondria. In regards to β-cells mitochondrial 
dysfunction, mitochondrial targeting miRNAs (mitomiR) may provide the missing link for 
mitochondrial dysfunction and β-cells observed in T2DM patients as Jagannathan and colleagues 
found differential expression of multiple miRNAs within the mitochondria in streptozotocin 
induced diabetic mice compared to healthy controls57. MitomiR have also been linked to both 
repression and enhancement of mitochondrial transcripts58,59, and even apoptosis56. The 
molecular mechanism mediating the observed miRNA driven effect on the mitochondria is 
however still unknown. The mitochondrial transcript lacks both 5’ UTR and cap and only has a 
poly(A) tail for 3’ UTR. Detection of GW182, a central scaffolding protein for cytosolic miRNA 
regulation, within the mitochondria has been unsuccesful58. These fact means that classic reporter 
assays were regulation is measured in the cytosol, will not reflect a mitochondrial environment, 
where novel interactions may mediate translational regulation in means different from the 
canonical pathway described. Therefore a reporter assay specific to the mitochondrial matrix is 
needed, to determine miRNA effects beyond canonical regulations.  
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2 Aim of the study 
The detection of MiRNA and the AGO proteins within the mitochondria provides a possible 
explanation for mitochondrial dysfunction observed in β-cells prior to the development of T2DM. 
However currently the toolset for in silico detecting of microRNA targets are unsuitable for the 
mitochondrial transcriptome, as the in silico approaches are based on canonical base pairing 
observed from nuclear transcribed mRNAs, and the golden standard for validation is reporter gene 
assays, where the regulation is performed in the cytosol. The purpose of this thesis was to try to 
determine if potential mitomiRs can be identified in silico with a bioinformatic approach and if the 
over expression of the proposed mitomiR induced a phenotype related to mitochondrial function. 
Any effect found by a “classical” reporter gene assay, might not reflect intra-mitochondrial effects, 
thus it was attempted to construct a method for determining intra-mitochondrial miRNA 
regulation as well.  
This thesis include three different experiments; The first part of the study was to determine the 
presence of miRNA target sites within the mitochondria genome in silico and selected targets from 
this approach were tested with a “classical” reporter gene assay. The second part of the study 
were to evaluate if a mitochondrial dependent phenotype could be observed in β-cell model (INS-
1e) in response to the over expression of these miRNA; The measured parameters were 
mitochondrial size, membrane potential,  superoxide production as well as insulin secretion due to 
its intimately connection to mitochondrial function. For a better understanding of the phenotypes 
observed by miRNA over expression, and in silico prediction of miRNA effect on biological 
processes were also performed. The third part of the study was to construct and test a modified 
reporter gene assay which measures the reporter gene expression in the mitochondrial 
compartment instead of the cytosol. 
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3 Methods 
3.1 Detection and validation of mitochondrial miRNA target sites 
Most available miRNA target site prediction tools do not include the mitochondrial genome in the 
database, and the algorithms are optimized for canonical target sites in the 3’ UTR, thus a custom 
algorithm was designed. The algorithm was designed to find sites within the mitochondrial genes 
coding strand (CDS), which aligned to the seed region of a miRNA. Conservation of the target site 
and the miRNA between humans, mice and rats were considered as well, conservation was chosen 
as a criterion since a functional important miRNA binding site could be expected to be conserved 
as similar conservation is also known from miRNA target sites within the nuclear genomes41. An 
overview of the process is depicted in Figure 11. Selected target sites were tested with a reporter 
gene assay. 
 
 
Figure 11 – miRNA target site prediction algorithm: Simple overview of the algorithm applied for miRNA target site 
detection and selection. 
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3.1.1 miRNA target site prediction 
The current version of Basic local alignment search tool (BLAST) standalone application; Blast-
2.2.30+ [02.03.2015] was obtained from The National Center for Biotechnology Information (NCBI) 
and installed according to the instructions60. The mitochondrial genome sequences were obtained 
from NCBI with the accession numbers; NC_012920.1, NC_001665.2 and NC_005089.1 for human, 
rats and mice respectively [02.02.2015]. The mature miRNA sequences for the three species were 
downloaded from miRBase database, Release 21 of June 2014 [09.02.2015]35. The miRNA list was 
filtered so only miRNA common among all 3 species was kept.  
A nucleotide BLAST was performed against each of mitochondrial genome, using the human 
miRNA sequence from the filtered miRNA sequences as query. The BLAST were adjusted to the 
following parameters; short query size, word size 5, evalue of a 1000, dust turned off, penalty -4 
and reward 5 for mismatch and matches, gap opening 8 and gap extend 6 for gapped alignment 
and output as XML. Short queries will reap low alignment scores, due to their short stretches, so 
this option optimizes the way the algorithm interprets the alignment scores. Word size 4 sets the 
initial lookup sequence to 4 nucleotides with 100% alignment. Evalue is the number expected hits 
found by chance and caps the maximal number on hits returned for each query sequence, by 
setting this high, all hits found are returned in the results. The Dust filter removes initial hits from 
the initial lookup table based on compositional bias e.g. low complexity of the DNA regions due to 
repeats or similar. Penalty is the score given to a nucleotide mismatch, reward is for a nucleotide 
aligned, gap opening is the penalty for having an initial one nucleotide gap in the alignment and 
gap extend is the penalty for each additional nucleotide in the gapped alignment. The XML output 
was chosen as the preferred output for further filtering in Microsoft® excel™ 2007. The result of 
these options is that the inherent filtering of the algorithm is removed and the stringency is at 
lowest possibly setting61, so all aligned hits are reported in the results. 
 
3.1.2 Filtering and sorting of target sites 
After the BLAST, the hits for each species was imported to Microsoft® excel™ 2007 and pre-filtered 
in several steps so that those hits that could not conform to the criteria listed in Table 1 were 
removed: 
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Table 1 – Exclusion criteria: 
1 miRNA reported without any hits. 
2 Hits with less than 5 nucleotides aligned in the seed region. 
3 Hits with more than a single nucleotide gap in the seed region. 
4 Hits with a gap in seed region, but not a complimentary alignment of the 17-25 nucleotide region 
of the miRNA within 30 nucleotides on the mitochondrial genome, 
5 Hits were the alignment mapped to outside the seed region. 
6 Hits not mapped to protein encoding sequences. 
7 Hits not antiparallel to the coding strand. 
8 Hits not shared between the mitochondrial genome of Human, Rat and mice 
 
The remaining hits were sorted to contain only hits from pancreatic islet as determined from qPCR 
data of β-cell islets in rats provided by post doc Sofia Salö (personal communication). Four of the 
remaining miRNA hits was chosen for further evaluation, the criteria for evaluation was based 
miRNA expressed in pancreatic β-cells62, detected in mitochondria63, involved in β-cells 
development64 and differentially expression in DM patients57. Conservation was defined by visual 
inspection with Clustal X265. 
 
3.1.3 Reporter gene Assay 
The purpose of the reporter gene assay is to determine the effect of a regulatory DNA sequences, 
such as promoters, and other regulatory DNA elements. The reporter assay is constructed by 
appending the regulatory DNA sequence to a reporter gene, so that the reporter gene is under the 
control of the regulatory sequence. The regulatory abilities of the tested sequence are then 
inferred from the effect observed on the reporter gene expression. The INS-1e cells used are 
derived from rattus norvegicus, so the miRNA target sites to be tested will be those found in the 
mitochondrial genome (NC_001665.2) from rattus norvegicus, the miRNA target sequence will be 
cloned into the 3’UTR of firefly “Photinus pyralis” luciferase gene (luc2).  Luc2 is an ideal reporter 
gene as it can be easily and reliably quantified, and have minimal effect on cell growth and 
behavior66. The Luc2 gene is expressed from an Sv40 promoter in the pGL4.13 vector (Promega, 
Madison, WI, USA). In order to compare the different samples the reporter assay will need to be 
normalized. Normalization can be done to factors related to the global expression levels of the 
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cells, as total protein content or by using the reporter gene in conjunction with a normalization 
gene. For the testing of the miRNA sequence a normalization vector was used with the 
normalization gene betagalactosidase (lacZ) under the control of the constitutive cytolomegavirus 
promoter (CMV). The additional benefit of using a normalization gene is that every sample is 
normalized for transfection efficiency as well as global expression levels. The modified pGL4.13 
reporter gene vector containing either the wildtype (wt) or an mutated sequence (mut) and the 
normalization vector was transfected to the INS-1e cells in conjunction with a stemloop miRIDIAN 
miRNA mimic or a negative control (Dharmacon, Lafayette, CO, USA)(Table 2). A positive and 
negative control in the form of a Luc2 gene coupled to a miR29a-3p perfect match and a miR29a-
3p scrambled site were included. The INS-1e cells were then be grown for 48hrs in Roswell Park 
Memorial Institute (RPMI) 1640 glutamax media (Thermo Fischer scientific, Pailey, Scotland, UK) 
before being assayed, the protocol for the transfection can be found in the appendix under the 
heading “Protocols for reporter gene assay”. INS-1e cells are derived from rattus norvegicus 
pancreatic cell line that maintains β-cell morphology and GSIS so it can be used as a β-cell model67. 
The protocols for the care and maintenance of the INS-1e cell culture can be found in the appendix 
under the heading “Protocols for the care of INS-1e cell culture”. The data from the wt and mut 
reporter construct conditions were normalized to the mean of the reporter gene construct 
containing the wt insert, but not co-transfected with a miRNA. Statistics comparison between the 
different conditions were performed using Student’s independent T-test as the samples were 
unpaired, but follow an equal distribution around the mean. 
 
Table 2 – miRIDIAN microRNA mimics, catalog number and sequence of the primary strand: 
miRIDIAN*  
*These are stemloops sequences, with modified passenger strands to 
increase incorporation into the miRISC of the named strand 
Sequence of primary strand 5’ – 3’ 
miRIDIAN microRNA Rat rno-miR-29a-3p - Mimic 
Catalog nr: C-320321-05-0005 
UAGCACCAUCUGAAAUCGGUUA 
miRIDIAN microRNA Mouse mmu-miR-125a-5p – Mimic 
Catalog nr: C-310392-07-0002 
UCCCUGAGACCCUUUAACCUGUGA 
miRIDIAN microRNA Mouse mmu-miR-152-3p – Mimic 
Catalog nr: C-310427-07-0002 
UCAGUGCAUGACAGAACUUGG 
miRIDIAN microRNA Mouse mmu-miR-223-3p – Mimic 
Catalog nr: C-310579-07-0002 
UGUCAGUUUGUCAAAUACCCCA 
miRIDIAN microRNA Mimic Negative Control #2 
Catalog nr: CN-002000-01-20 
UUGUACUACACAAAAGUACUG 
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3.1.4 Cloning of reporter gene vectors 
The proposed miRNA targets will be inserted into the plasmid vector pGL4.13 in the 3’ UTR of luc2, 
see Figure 12. The pGL4.13 was double digested with the endonucleases XbaI and FseI (New 
England Biolabs, Ipswich, MA, USA) according to manufactures recommendations. The vector 
backbone is separated with gel electrophoresis (GE) and extracted and purified with QIAquick Gel 
Extraction Kit (Qiagen, Hilden, Germany). The purified backbone contains 2 different sticky ends 
from the endonuclease digestion which prevent relegation and was subsequently used to make all 
the reporter constructs for the different miRNA target sites. As the experiments were performed 
in INS-1e cells, it was decided to use the miRNA target sequence derived from rats, as the insert in 
the reporter gene vectors. The wt and mut insert was designed so that they contained the 
mitochondrial miRNA target sites and five neighboring nucleotides flanking each side, each insert 
also contained a different restriction site for later controls. The ends of the insert will form 
complimentary sticky ends to the pGL4.13 backbone, ensuring. The mutated controls for the insert 
were made my scrambling bases in the proposed seed region. The scrambling were tested, using 
nucleotide BLAST and the full sets of miRNA as query, to ensure now new seed region were made 
by the process. The insert was obtained by purchasing two complimentary DNA oligoes with the 
desired sequence (TAG Copenhagen A/S, Copenhagen, Denmark), which subsequently was 
annealed to form a double stranded insert, the sequence of the inserts are listed in Table 3. The 
vector backbone and the double stranded insert was mixed in 1:3 eqimolar ratios and ligated with 
Roche rapid DNA ligation kit (Sigma Aldrich, St. Louis, MO, USA) according to the manufactures 
instruction for sticky end ligation. 
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Figure 12 – simplified overview of pGL4.13: The restriction sites for FseI and XbaI is shown between the Luc2 gene 
and the Sv40 poly(A) region. 
 
 
Table 3 – miRNA oligoes for target site inserts: 
miRNA target site Sequence Restriction 
site 
miR29a-3p wt 5’- CTAGAAGCTTGGGTTGCGGCTATTTATAGTTGTGCTACTTGAGGCCGG -3’ HindIII 
mt-ND6 site 5'- CCTCAAGTAGCACAACTATAAATAGCCGCAACCCAAGCTT -3'   
miR29a-3p mut 5’- CTAGACTCGAGGGGTTGCGGCTATTTATAGATGTTCTGCTTGAGGCCGG -3’ XhoI 
mt-ND6 site 5'- CCTCAAGCAGAACATCTATAAATAGCCGCAACCCCTCGAGT -3'   
miR125a-5p wt 5’- CTAGAGAGCTCAGAAGGAGAATCAGAATTAGTCTCAGGCTTTAACGGCCGG -3’ SacI 
mt-ND1 site 5'- CCGTTAAAGCCTGAGACTAATTCTGATTCTCCTTCTGAGCTCT -3'   
miR125a-5p mut 5’- CTAGAGGTACCAGAAGGAGAATCAGAATTACTTCGAGGCTTTAACGGCCGG -3’ KpnI 
mt-ND1 site 5'- CCGTTAAAGCCTCGAAGTAATTCTGATTCTCCTTCTGGTACCT -3'   
miR-152-3p wt  5’- CTAGACAGCTGCCATCATAGCTGGCTTCGTCCACTGATTCCCGGCCGG -3’ PvuII 
mt-COX1 site 5'- CCGGGAATCAGTGGACGAAGCCAGCTATGATGGCAGCTGT -3'   
miR-152-3p mut  5’- CTAGAGGATCCCCATCATAGCTGGCTTCGCACGCTTATTCCCGGCCGG -3’ BamHI 
mt-COX1 site 5'- CCGGGAATAAGCGTGCGAAGCCAGCTATGATGGGGATCCT -3'   
miR-223-3p wt  5’- CTAGAGAGCTCAATAATTGGAGGCTTCGGGAACTGACTTGTACGGCCGG -3’ SacI 
mt-COX1 site 5'- CCGTACAAGTCAGTTCCCGAAGCCTCCAATTATTGAGCTCT -3'   
miR-223-3p mut  5’- CTAGAGGTACCAATAATTGGAGGCTTCGGGAGCTCAATTGTACGGCCGG -3’ KpnI 
mt-COX1 site 5'- CCGTACAATTGAGCTCCCGAAGCCTCCAATTATTGGTACCT -3'   
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3.1.5 Vector Amplification 
Amplifications were performed in chemically competent DH5-α E. coli cells. The competency refers 
to their ability to take up extracellular DNA from the environment. After successful transformation 
the vector can be replicated and amplified during cell growth due to the presence of an E. coli 
origin of replication site within the vector.. The chemical competency is induced to E. coli cells by 
cooling down exponential growing cells to near freezing. The cold temperature decrease the 
fluidity of the cell membranes causing the outer and inner membrane to fuse through the cell wall 
in susceptible areas, such as near pores and channels, the cell wall matrix would otherwise 
prevent DNA passage. The addition of buffers containing cationic divalent ions such as calcium and 
rubidium will bind to the anionic macromolecules such as lipopolysaccharides (LPS) in the 
membrane and DNA. It has also been proposed that cationic ions like chloride enters the cells and 
cause them to swell, stretching the membranes and breaking even more of the cell wall further 
improving passage for DNA. During the transformation DNA is added to the ice cold cells and the 
DNA will form stable coordination complexes with the cationic divalent ions and LPS at the 
membrane surface. Subsequent heat shock will then facilitate the movement of the DNA across 
the membranes and conclude the transformation68. Successful transformants can then be 
screened based on a selective maker – most often antibiotic resistance. The protocols regarding 
preparation of chemically competent cells as well as the transformation and screening procedure 
can be found in the appendix under the heading “Protocols for transformation”. 
 
3.1.6 Transfection with lipofectamine® 2000 
Transfection can be performed by various means, but for this experiment the plasmid vectors and 
miRNA mimics are to be delivered to the INS-1e cells with lipofilic aggregates as carriers, utilizing 
Lipofectamine® 2000 (Invitrogen, Pailey, Scotland, UK). Lipofectamine® 2000 reagent is proprietary 
formulation and the formula is not disclosed, but from the patent application it is known that 
lipofectamine is a mix of dioleylphosphatidyl ethanolamine (DOPE) and 2,3-di-oleyloxy-N-
[2(spermine-carboxamido)ethyl]-N,N-dimethyl-l-propan-aminium (DOSP A). Where DOSP A acts as 
the cationic agent that binds to the Nucleic acids and DOPE is a neutral helper lipid which helps in 
the aggregate formation69. The aggregate shields the anionic charge of the nucleic acid and 
maintain a cationic outer charge which is attracted to the cell membrane where it is endocytosed. 
Inside the cell the aggregate is dissolved and the nucleic acids escape the endosome by an 
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unknown mechanism. The nucleic acid can then get incorporated into the nucleus of dividing cells 
during the reassembly of the nucleus in the telophase. For this experiment 1.25*105 INS-1e cells 
were transfected with 50µl Opti-MEM® media (Thermo Fischer Scientific, Pailey, Scotland, UK) 
containing 2% Lipofectamine® 2000, 600ng reporter gene vector, 50ng normalization vector and 
25pmol miRNA mimic. The specific protocol can be seen in the appendix under the “Protocol for 
the reporter gene assay”. 
 
3.2 Mitochondrial derived phenotypes 
The effect of the chosen miRNA on the GSIS was measured in INS-1e cells. GSIS is intimately linked 
to mitochondrial function, and can indirectly be used to determine potential effect of the miRNA 
on the mitochondrial function. The assay will be performed by over expression of the miRNA, 
followed by measurement on the insulin secretion, total protein content and qPCR of the miRNA 
levels. GSIS is a method where the cellular insulin secretion is measured in response to different 
conditions, in this study the condition was the over expression of a given miRNA. The miRNA was 
over expressed by transfecting 200pmol miRIDIAN mimics into 8million INS-1e cells with 
nucleofection, see below. The INS-1e cell was then grown for 72hrs in RPMI media (Thermo 
Fischer Scientific, Pailey, Scotland, UK) with 5mM glucose.  Before being assayed the INS-1e cells 
were incubated for 3hrs in RPMI media with 3mM glucose. The Insulin release was measured by 
changing the media to Krebs-Ringer bicarbonate buffer (KRBH) with either 3 or 20mM glucose. The 
KRBH were then collected and centrifuged after 2 hrs, and the insulin content of the supernatant 
measured. The insulin content was measured by competitive enzyme linked immunosorbent assay 
(ELISA) and compared to a defined rat insulin standard (gift from Hans Kofoed, Panum Institute) 
The cells were then washed and lysed and the total protein content was measured with BCA 
Protein Assay Kit and used to normalize the insulin levels, by dividing the insulin samples with the 
mean of the protein level. Comparisons between the samples were performed using Student’s 
independent T-test as the samples were unpaired, but follow an equal distribution around the 
mean. Successful nucelofection and over expression of the miRNA was measured with reverse 
transcriptase followed by qPCR after reverse transcription of the RNA. 
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3.2.1 Nucleofection 
Nucleofection is a special form of transfection based on Electroporation. The application exploits 
that a sufficiently strong external electric field will exceed the cellular membranes capacitancec. 
The membranes isolating lipid bilayer breaks down and water filled conductive pores are formed. 
In a solution of cells and nucleic acids, temporary pores are formed in the cells membranes 
(including the nucleus) in response to the large membrane potential gradient, the anode also 
attract the anionic nucleic acids moving them in the solution, repeated reversal of the polarity, 
ensures that the nucleic acid becomes equilibrated with the cellular compartment70. The spatial 
rearrangement allows the nucleic acid to enter the cells and even the nucleus compartment 
through the conductive pores see Figure 13. For this experiment an AMAXA nucleofector and 
nucleofector solution V (Lonza, Copenhagen, Denmark) using program T-030d was used to 
transfect 200pmol miRNA mimics to 8*106 INS-1e cells. 4*105 cells/well were then seeded into 
eight wells of a poly-lysine coated 24well cell culture plate. 1.6*106 cells were seeded in an Ø3cm 
poly-lysine coated cell culture plate used for RNA purification. The remaining 3.2*106 INS-1e cells 
were seeded in an Ø6cm poly-lysine coated cell culture plate and used for protein extraction (not 
used in the experiment). The Fluorescent rhodamine labeled siRNA was included to determine 
transfection efficiency. Detailed protocols regarding the specific method can be found in the 
appendix under the heading “Protocols for transfection”.  
 
 
Figure 13 – The movement of charged molecules in an electrified solution: When an electric field is applied across 
and insulating bilayer, a membrane potential is build. The membrane potential exceeds the membrane capacitance 
                                                     
c
 Ability to store an electric charge. 
d
 T-030 is empirically tested in house to perform best with miRNA transfection into INS-1e cells. 
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and the bilayer breaks and form conductive pores. Charged molecules move due to electrostatic attraction and are 
homogenized in the solution, entering the conductive pores as well. When the electric field is relieved the pores mend 
themselves, trapping the charged molecules inside. (Picture adapted from 
71
) 
 
3.2.2 ELISA 
ELISA is a method used to detect the presence of an antigen by capturing it with an antibody or 
the presence of an antibody by capturing it with an antigen. Several variant of the ELISA method 
exists, but for this experiment a competitive ELISA approach were used. Nunc MaxiSorb 96 well 
microtitter plates (Sigma Aldrich, St. Louis, MO, USA) were coated with a 1:1000 dilution of 
AB8522 (Abcam, Cambridge, UK) a rabbit antibody against guinea pig antibodies as the primary 
antibody. The microtitter plates were then recoated with a 1:1000 dilution of PC2005 (gift from 
Hans Kofoed, Panum Institute) an insulin specific guinea pig secondary antibody. The insulin 
containing supernatant was then added to the wells together with a defined amount of competing 
peroxidase (PO) conjugated insulin. During an overnight incubation at 4°C the insulin and PO 
conjugated insulin competed for binding with the PC2005 and reached equilibrium. The wells were 
then washed and the substrate 3,3',5,5'-tetramethylbiphenyl-4,4'-diamine (TMB) (Bio-rad, 
Copenhagen Denmark) added, The PO then oxidized the TMB and amount of oxidization depends 
on the amount PO-insulin, making the chromogen formation inverse to the insulin present in the 
sample. The samples were measured at 450nm, and had the background measured at 690nm and 
subtracted. The GSIS data were normalized to the protein content of the individual wells, A 
detailed protocol can be found in the appendix under the heading “Protocols for GSIS”.  
 
3.2.3 BCA protein assay 
The INS-1e cells was lysed with Radioimmunoprecipitation assay buffer (RIPA buffer) before the 
protein was measured. An aliquot of the lysis buffer was added an alkaline buffer containing Cu2+, 
bicinchoninic acid (BCA) and sodium tartrate. The Cu2+ ions are chelated with proteins, due to the 
alkaline environment and the presence of sodium tatrate, this process reduce the Cu2+ to Cu+. BCA 
then reacts with Cu+ and creates a strong purple color, increasing the sensitivity of the colorimetric 
reaction. For this experiment Pierce™ BCA Protein Assay Kit (Thermo Fischer Scientific, Pailey, 
Scotland, UK) were used according to the manufactures protocol. 
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3.2.4  RNA extraction, cDNA synthesis and qPCR 
RNA was extracted using Acid guanidinium thiocyanate-phenol-chloroform extraction based 
method. The method works by using two distinct phases; an upper aqueous phase, and a lower 
dense phase consisting of phenol and chloroform. The phenol and chloroform lyses the cell 
membrane and releases the intracellular content. Nucleic acids are solubulised in the aqueous 
phase, but in acidic conditions only RNA moves to the water phase were it can be collected. 
Guanidinium thiocyanate is added to denaturize the proteins, releasing any bound DNA and RNA 
in the process. The RNA can then be extracted from the water phase by 2-propanol precipitation72. 
For this experiment TRI reagent (Sigma Aldrich, St. Louis, MO, USA) were used according to the 
manufactures instruction. cDNA and qPCR of the miRNA were performed using “looped primers” 
with the method described by Martha Kramer73 (Figure 14), except that quantification of the cDNA 
was performed using qPCR. The method use a single primer for reverse transcriping (RT) each 
microRNA, which forms a hairpin loop so only one primer is needed for reverse transcriptase. TFIIB 
were used for normalization, but the RT performed without a stem-loop primer, but by using both 
a forward and reverse primer. The RT was performed with SuperScript® III Reverse Transcriptase 
(Invitrogen, Pailey, Scotland, UK) and the qPCR with QuantiTect SYBR® Green PCR Kits (Qiagen, 
Hilden, Germany) both according to the manufactures recommendation. The PCR cycling 
conditions are found in the appendix under the heading “Protocols for GSIS” and the primers can 
be seen in Table 4. 
Figure 14 – Reverse transcriptase and qPCR 
of miRNA using looped primers: Nucleic acid 
reagents used for and intermediate products 
generated in this method. A: Mature miRNA 
(blue). A-H: Light blue lines show the 
boundary of the mature miRNA sequence 
within the RT and qPCR reagent sequences; 
open arrowheads indicate directions of 
polymerization. B: The last 6 nt of the 3’ stem-
loop primer annealed to the last 3’ nt of the 
mature miRNA and elongated by reverse 
transcriptase (RT). C: First strand cDNA after 
polymerization, D: and heat denaturation. E: 
Forward primer with added and binds to 5′ of 
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the cDNA. F: Second strand cDNA. G: Reverse primer is added. (Hydrolysis probe was omitted in this experiment as 
quantification was performed with quantificative PCR) H: Final PCR product defined by the 5′ termini of the forward 
and reverse primers. (Picture and legend adapted from 73) 
 
Table 4 – Primers used for reverse transcriptase and qPCR: 
Primers Primer sequence (5’ – 3’) 
miR-125a-5p looped primer CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTCACAGGT 
miR-125a-5p qPCR primer ACACTCCAGCTGGGTCCCTGAGACCCTTTAAC 
miR-152-3p looped primer CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGCCAAGTTC 
miR-152-3p qPCR primer ACACTCCAGCTGGGTCAGTGCATGACAGA 
miR-223-3p looped primer CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTGGGGTAT 
miR-223-3p qPCR primer        ACACTCCAGCTGGGTGTCAGTTTGTCAAAT 
Universal reverse primer -  looped RT TGGTGTCGTGGAGTCG 
TFIIB forward and RT primer GTTCTGCTCCAACCTTTGCCT 
TFIIB Reverse primer TGTGTAGCTGCCATCTGCACTT 
3.2.5 MiRNA effect on mitochondria 
The miRNAs were over expressed by transfecting 200pmol miRNA mimics into 6*106 INS-1e cells 
with nucleofection as described in section 3.2.1. The cells were then seeded with 1*106 pr. well in 
a poly-lysine coated 6-well plate. The INS-1e were then grown for 72hrs in RPMI 1640 glutamax 
media before being dyed with the fluorescent dyes; Mitotracker deep red (MTDR) (Mitotracker 
Deep Red FM (Invitrogen cat. no. M22426), Tetramethylrhodamine, methyl ester (TMRM) (Sigma 
Aldrich, St. Louis, MO, USA) and MitoSOX (Molecular Probes, Invitrogen, cat. no. M36008) for 30 
minutes, before being trypzinised to single cell suspension and analyzed on the FACS Calibur 
(Becton Dickinson, Franklin lakes, NJ, USA). MTDR dye intensity is related to the mitochondrial 
mass, the dye sequestered in the mitochondria relative to the mass of the mitochondria, MTDR 
has a fluorescent excitation spectrum at 644nm and an emission spectrum of 665nm. The TMRM 
is reversible sequestered in the mitochondria matrix depending on mitochondrial membrane 
potential, with the dye intensity related to increasing amount of TMRM in the mitochondria in 
relation to increased membrane potential. TMRM has a fluorescent excitation spectrum at 550nm 
and an emission spectrum of 573nm. MitoSOX is sequestered in the mitochondria, where it is 
oxidized by superoxide (O2
-), a mitochondria specific ROS. The superoxide oxidized mitoSOX has a 
fluorescent excitation spectrum at 400nm and an emission spectrum of 590nm, which can be 
measured to determine the amount of superoxide generated relative to the intensity of the 
emission74.  
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3.2.6 Functional annotation of miRNA targets 
miRNA targets enriched in specific biological processes were determined utilizing The Database for 
Annotation, Visualization and Integrated Discovery v. 6.7 (DAVID)75. DAVID evaluates if the entries 
on a gene list occurs more often than expected in certain pathways, biological processes or 
functional groupings. The comparison is limited to a background list, which consist of the genes 
expressed in the target tissue. For this experiment the gene list will be prepared from conserved 
miRNA targets found in rattus norvegicus found using the Targetscan algorithm v. 7.0 developed 
by Lewis, B.P and colleagues76,77. A transcriptome of INS-1e should be used as the background, 
however the transcriptome of INS-1e was not public available, so the transcriptome of the related 
cell line INS-1 832/1378 were used as a substitute as it exhibit similar GSIS. The results was limited 
to rattus norvegicus and obtained as functional annotation clusters. To limit the result only the 
most significant clusters with enrichment score of ≥5.0e, in biological processes 
(GOTERM_BP_FAT) were reported. 
 
3.3 Mitochondrial reporter gene assay 
The reporter gene assay in its current form is limited to validate cytosolic expression only, and as 
such do not clarify if the miRNA would be able to translocate to the mitochondria and exerts an 
effect, therefore an alternative assay to evaluates mitochondrial regulation were devised and 
tested. A luc2 reporter gene that can only be translated in the mitochondria were made. The 
differential translation potential was obtained by exploiting differences between the universal 
genetic code and the unique deviations of the mitochondrial codon translation see  
Table 5. The firefly luciferase luc2 (AAV52869.1) used as a reporter gene contain one isoleucine 
codon (aa146) that encodes isoleucine in the cytosol, but methionine in the mitochondria, this was 
changed to an ATT codon that is conserved for isoleucine in the mitochondria as well. 2 
tryptophan codons (aa417 and 426) were then changed to TGA codons which encodes the 
cytosolic stopcodons. The 438A>T substitution made the Luc2 gene universally translatable and is 
named luc2uni for later references and the 438A>T + 1251G>A + 1278G>A substitutions would only 
be translatable in the mitochondria and is labeled luc2mito.  
                                                     
e
 Enrichment score is the negative logarithm to the geometric mean of the combined P values. 
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Table 5 – mitochondrial codon deviation: 
Codons: TGA ATA AGA AGG 
Universal genetic 
code: 
Stop Isoleucine Arginine Arginine 
Vertebrate 
Mitochondrial 
genetic code: 
Tryptophan Methionine Stop Stop 
luc2 - wildtype 0 1 0 0 
luc2  - universal 0 0 0 0 
luc2 –  only 
mitochondria 
2 0 0 0 
 
The variants were put under the control of either a cytosolic or mitochondrial promoter. As Sv40 is 
already present in the pGL4.13 vector it was used for cytosolic expression, and the mitochondrial 
promoter were a full length D-loop. The expected levels of transcription, translation and luciferase 
activity are depicted in Table 6.  
 
Table 6 – Expected expression levels of the reporter gene constructs: 
Plasmid 
pGL4.10[D-
loop, luc2] 
pGL4.10[D-
loop, luc2uni] 
pGL4.10[D-
loop, luc2mito] 
pGL4.13[Sv40, 
luc2] 
pGL4.13[Sv40, 
luc2uni] 
pGL4.13[Sv40, 
luc2mito] 
Cytosol 
RNA + + + +++ +++ +++ 
Protein 
+ + +  
(truncated) 
+++ +++ +++ 
(truncated) 
Luciferase 
activity 
+ + none +++ +++ none 
Mitochondria 
RNA +++ +++ +++ + + + 
Protein +++ +++ +++ + + + 
Luciferase 
activity 
? 
(Mutated) 
+++ +++ ? 
(Mutated) 
+ + 
 
3.3.1 Luciferase mutagenesis 
To create the luc2uni and luc2mito three base pair substitutions were required. The mutations were 
induced with overlap extension PCR mutagenesis. This method is a variant of site directed 
mutagenesis, where PCR amplification is performed on a DNA sequence in 2 steps. The first two 
PCR reactions will be performed where either the forward or reverse primers contain the desired 
mutation, but are otherwise complimentary to the DNA. The first set of primers will amplify a 
product from the mutated site and upstream, and the second set from the mutated site and 
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downstream. The product from the two reactions is purified and used as template in a PCR 
reaction together with the forward and reverse primers not carrying mutations from the previous 
amplification. The PCR product then contains a full length product containing a mutated area79 
(Figure 15). The two mutagenesis reactions were performed with the primers listed in Table 7, the 
sequence is listed in Table 8. The cycling conditions are described in the appendix under the 
heading “Protocols for cloning”. 
 
 
C 
Isoleucine change  
 
Forward Isoleucine               5’- GCTACCGATCATTCAAAAGATCATCATCATG -3’ 
                                     |||||||||||| |||||||||||||||||| 
Luc2                5’- ...TGCAAAAGAAGCTACCGATCATACAAAAGATCATCATCATG... -3’ 
                           |||||||||||||||||||||| ||||||||| 
Reverse Isoleucine     3’- ACGTTTTCTTCGATGGCTAGAATGTTTTCTAG -5’ 
Tryptophan change 
 
Forward – Trp to Stop 5’- CATCGACAAGGACGGCTGACTGCACAGCGGCGACATCGCCTACTGAGACGAGGACGAGCACTTC -3’ 
                          |||||||||||||||||| |||||||||||||||||||||||||| |||||||||||||||||| 
Luc2               5’- ...CATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTC... -3’ 
                          |||||||||||||||||| |||||||||||||||||||||||||| |||||||||||||||||| 
Reverse – Trp to Stop 3’- GTAGCTGTTCCTGCCGACTGACGTGTCGCCGCTGTAGCGGATGACTCTGCTCCTGCTCGTGAAG -5’ 
Figure 15 – Overlap extension PCR mutagenesis and the pGL4.13 vector and primers: A: Schematic overview of PCR 
mutagenesis, two PCR reactions are performed one with primers a and c, and one with primer c and d, primer c and b 
contains the mutated sequence. The product AB+ and CD+ are then used as templates in a new PCR reaction with 
primers a and d. The final AD product contains the mutated area. B: pGL4.13 vector with the Luc2 insert, and the 
orientation of the primers used for the mutagenesis. C: overview of the two mutation sites. (Picture adapted from 79 
and 41).  
A                                                                       B 
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Table 7 – Primers used for overlap extension PCR mutagenesis 
Product Primer a Primer b Primer c Primer d Template 
luc2uni Forward – 
universal 
Reverse - 
isoleucine 
Forward – 
isoleucine 
Reverse –  
universal 
pGL4.13 
with Luc2 
luc2mito Forward – 
universal 
Reverse – 
 Trp to stop 
Forward –  
Trp to stop 
Reverse –  
universal 
Luc2uni 
 
Table 8 – Primers sequence for overlap extension PCR mutagenesis: 
Primer name Primer sequence 5’ to 3’ 
Forward – 
Universal 
GTAGTGAGGAGGCTTTTTTGGAG 
Reverse – 
universal 
GTGGTTTGTCCAAACTCATCAATG 
Forward – 
Isoleucine 
GCTACCGATCATTCAAAAGATCATCATCATG 
Reverse – 
Isoleucine 
GATCTTTTGTAAGATCGGTAGCTTCTTTTGCA 
Forward – 
Trp to Stop 
CATCGACAAGGACGGCTGACTGCACAGCGGCGACATCGCCTACTGAGACGAGGACGAGCACTTC 
Reverse – Trp 
to Stop 
GAAGTGCTCGTCCTCGTCTCAGTAGGCGATGTCGCCGCTGTGCAGTCAGCCGTCCTTGTCGATG 
3.3.2 Cloning of mitochondrial only expression assay vectors 
The PCR products Luc2uni and Luc2mito and the pGL4.13 and pGL4.10 vectors (Promega, Madison, 
WI, USA) was double digested with HindIII and XbaI (New England Biolabs, Ipswich, MA, USA) 
according to the manufactures description, before being separated by gel electrophoresis and 
purified with qiagen gel extraction kit (Qiagen, Hilden, Germany). The pGL4.10 and pGL4.13 
backbone was then ligated in equimolar ratios of 1:3 with the purified Luc2uniand Luc2mito using  
Roche rapid ligation kit(Sigma Aldrich, St. Louis, MO, USA) according to the manufactures 
recommendations for sticky end ligation. The new pGL4.10 [luc2uni] and pGL4.13 [luc2uni] vector 
and all other vector amplifications were amplified as described in “section 3.1.6”, before being 
sequenced. In order to obtain a mitochondrial promoter, the human D-loop was amplified using 
Primers with 5’ overhangs containing restriction sites for KpnI in the forward primer and HindIII in 
the reverse primer see Table 9. The amplified D-loop and pGL4.10[luc2uni] and pGL4.10[luc2mito] 
was double digested with the endonucleases KpnI and HindIII (New England Biolabs, Ipswich, MA, 
USA according to manufactures recommendations. The digested PCR product and the vector were 
then separated with gel electrophoresis, extracted and purified. The purified vector backbone and 
PCR product was ligated in equimolar ratio of 1:3 with Roche rapid ligation kit according to the 
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manufactures recommendations for sticky end ligation. The new pGL4.10 [D-loop, luc2uni] and 
pGL4.10 [D-loop, luc2mito] vectors was amplified. 
 
Table 9 – D-loop amplification primers: 
Primer name Primer sequence 5’ – 3’ 
D-loop forward primer AAAAAGGTACCAAAAATAATTTAAACTATTCTCTGTTCTTTCATGGG 
D-loop reverse primer AAAAACTCGAGAAAATCTTTGAGGAGGTAAGCTACATAAAC 
 
3.3.3 Testing the mitochondrial expression assay 
The mitochondrial expression assay is in most ways identical to the reporter gene assay described 
in “section 3.1.3” and transfecting the vectors inside INS-1e cells in conjunction with the CMV-LacZ 
normalization vector with the Lipofectamine® 2000 method described in “section 3.1.6”, with the 
only difference that instead of a miRNA mimic 10ng of a TFAM or peroxisome ppar gamma co-
activator 1 alpha(PGC1a) pcDNA3.1(Invitrogen, Paisley, Scotland, UK) under the control of a CMV 
promoter were co-transfected. TFAM enhances mitochondrial transcription and PGC1a is a 
transcription factor of the TFAM gene, and should theoretically increase expression from the D-
loop promoter. The INS-1e cells were grown for 48hrs in RPMI 1640 glutamax media before being 
assayed. 
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4 Results 
4.1 Detection and validation of mitochondrial miRNA target sites 
The full list of known miRNAs were sorted so only those miRNA which were common between 
humans, mice and rats were kept, leaving 383 miRNA to be used as a query in the BLAST.  
 
Table 10 – miRNA overview: 
 Total miRNA (n) Uniquef miRNA (n)  
Homo Sapiens  2588 2067 
Mus Musculus 1916 1264 
Rattus Norvegicus 766 192 
 
The mitochondria of the human, mice and rat mitochondria were defined as databases in BLAST 
stand-alone utility V.2.2.30+. Then the common miRNA (human sequence) were blasted against 
the 3 mitochondria genomes with the specific search string: blastn –task blastn-short –word_size 5 
–evalue 1000 –gapopen 8 –gapextend 6 –reward 5 –penalty -4 –outfmt 5 –query “filename 
containing common miRNA” –db “mitochondria genome database” –out (filename for output). 
The BLAST results against the 3 mitochondrial genomes gave a total of 0.5 million hits. These hits 
were then filtered and sorted (Table 11). The hits were first prefiltered in excel according to 
criteria 1-5 in Table 1, section 3.1.2 removing all hits without proper base pairing reduced the total 
hits to 37193 hits. After pre-filtering the hits were annotated gene names and CDS orientation and 
filtered again according to criteria 6-8 in Table 1, section 3.1.2 reducing the number of hits to 529. 
The 529 hits were divided on 99 miRNA and the miRNA were compared to miRNA detected in rat 
pancreatic islet with qPCR by Post doc Sofia Salö (personal communication, unpublished data), 
leaving 37 miRNA with 187 potential mitochondrial targets. The full target list can be found in the 
appendix, under the heading “Mitochondrial miRNA targets sites”.  
 
 
 
 
                                                     
f
 Not found in either of the two other species. 
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Table 11 -  Filtering and sorting of miRNA hits: 
miRNA query 383 miRNA 
  
Total Hits from nucleotide BLAST 504315 hits 
   Homo Sapiens (NC_012920.1)    172172 hits 
   Mus Musculus (NC_005089.1)    164901 hits 
   Rattus Norvegicus (NC_001665.2)    167242 hits 
  
Hits retained after pre filtering 37193 hits 
  
Hits retained after sorting 529 hits divided on 99miRNA 
  
Sorted islet expressed miRNA only 187 hits divided on 37 miRNA 
 
In conjunction with my supervisor associate professor Louise Torp Dalgaard four miRNA were 
selected for further investigation; miR-29a-3p, miR-125a-5p, miR-152-3p and miR-223-3p. These 
miRNA were chosen for further investigations, the evaluation criterion involved the length of the 
annealed area in the seed region, conservation of their target site, localization to β-cells62, 
detected in mitochondria80,81 and by previous reported effects on β-cell function and 
development64. The compared miRNA targets sites are listed below. Nucleotides conserved 
between the species is marked with “*”, and base pairing between the miRNA and the CDS is 
marked with yellow for perfect base pairs and grey for wobble base pairs. The rattus norvegicus 
miRNA target site used for the reporter gene assay is written in bold.  
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miRNA-29a 
mIR-29a-3p and its effects represent an area of interest for this research group, and miR-29a was 
therefore included as a target when found in the final results. miR-29a has also been found in β-
cells by post doc Sofia Salö – unpublished data. miR-29a is known to regulate β-cell GSIS82 and 
detected in the mitochondria by PhD student Julian Geiger in unpublished data. miR-29a-3p has a 
hit in mt-ND6 in all three species, but the hit were not conserved between humans and rats and 
mice, below is the two different target sites listed, target site 2 were used for the insert. 
Target site 1 (mt-ND6 in human): 
Mir-29a-3p           3’- AUUGGCUAAAGUCUACCACGAU – 5’ 
RNO pos. 13744: 5’- CTTTTTATGGAGTTGGTAGTGTTCTACTTGTT -3’ (13776) 
HSA pos. 14356: 5’- TTAGCGATGGAGGTAGGATTGGTGCTGTGGGT -3’ (14388) 
MMU pos. 13753: 5’- GTGATTATAGAGGTTTTTTTAATTTGTGTGCT -3’ (13785) 
Conservation:        *    ** *** *     *  *      * *  
 
Target site 2 (mt-ND6 in rats and mice): 
Mir-29a-3p           3’- AUUGGCUAAAGUCUACCACGAU – 5’ 
                           : | ||||   :| |||||| 
RNO pos. 13612: 5’- GGGTTGCGGCTATTTATAGTTGTGCTACTTGA -3’ (13644) 
HSA pos. 14221: 5’- GTGCGGGGGCTTTGTATGATTATGGGCGTTGA -3’ (14253) 
MMU pos. 13621: 5’- GGGTAGCGGCAATATATAGTTGTGCTACTTGA -3’ (13663) 
Conservation:       * *  * ***  * ***  ** **    **** 
 
miRNA-125a 
miRNA-125a-5p is clustered with miR-let-7e and miR-99b on chromosome 19, and has a conserved 
target in mt-ND1. miR-125 and has been shown to be downregulated in mature β-cells as shown 
by post doc Sofia Salö – unpublished data, to be involved in pancreatic β-cell differentiation64. 
MiR-125-5p has also been located in the mitochondria of human myotubes83, and shown to have 
increased abundance in liver mitochondria, compared to the cytosol in mice63. 
Target site in mt-ND1: 
miR-125a-5p         3’- AGUGUCCAAUUUCCCAGAGUCCCU -5’ 
                          : |    ||   |||||||| 
RNO pos. 3352: 5’- AGAAGGAGAATCAGAATTAGTCTCAGGCTTTAAC -3’ (3385)      
HSA pos. 3909: 5’- CGAAGGGGAGTCCGAACTAGTCTCAGGCTTCAAC -3’ (3942) 
MMU pos. 3353: 5’- AGAAGGAGAATCAGAATTAGTATCAGGGTTTAAC -3’ (3384) 
Conservation:       ***** ** ** *** **** *** * ** *** 
 
miRNA-152 
MiR-152-3p has a conserved target in mt-COX1, and has been shown to be downregulated in 
mature β-cells as shown by post doc Sofia Salö – unpublished data. miR-152 was primarily chosen 
Discussion 
49 
 
due to the miRNA-gene complementarities and because miR-152 has also been shown to have 
decreased abundance in liver mitochondria, compared to the cytosol in mice63 and has previously 
been investigated for GSIS impact in INS-1 832/13 cells.84 
Target site in mt-COX1: 
miR-152-3p         3’- GGUUCAAGACAGUACGUGACU -5’ 
                        :|: |    ||:| |||||| 
RNO pos. 6486: 5’- CATCATAGCTGGCTTCGTCCACTGATTCCC -3’ (6515) 
HSA pos. 7067: 5’- CATCATAGGAGGCTTCATTCACTGATTTCC -3’ (7096) 
MMU pos. 6491: 5’- TATCATAGCAGGATTTGTTCACTGATTCCC -3’ (6520) 
Conservation:      *******  ** **  * ******** ** 
 
miRNA-223 
miR-223-3p has an conserved target in mt-COX1, and has been shown to be highly downregulated 
in mature β-cells as shown by post doc Sofia Salö – unpublished data. And downregulated in the 
pancreas of T2DM patients85, miR-223 expression has also been correlated to increased insulin 
secretion86. PhD student Julian Geiger detected miR-223 in mouse liver mitochondria – 
unpublished, and the differential downregulation of miR-223 in mice liver mitochondria compared 
to the cytosol has also been observed62. 
Target site in mt-COX1: 
miR-223-3p          3’- ACCCCAUAAACUGUUUGACUGU -5’ 
                        | ||  : || : :||||||| 
RNO pos. 5541: 5’- AATAATTGGAGGCTTCGGGAACTGACTTGTAC -3’ (5582) 
HSA pos. 6122: 5’- CATAATCGGAGGCTTTGGCAACTGACTAGTTC -3’ (6163) 
MMU pos. 5543: 5’- AATAATTGGAGGCTTTGGAAACTGACTTGTCC -3’ (5584) 
Conservation:       ***** ******** ** ******** ** * 
 
The miRNA target sites as described in “section 3.1.4” were inserted into pGL4.13 expressions 
vectors, successful insertion verified by sequencing (Beckman coulter genomics, Essex, UK). The 
experiments were performed in quadruplicates and repeated 3 times. And the results from the 
transfections were normalized to the samples of the wildtype sequence without a co-transfected 
mimic, see Figure 16.  
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Figure 16 – reporter gene assay data: A – C: Expression levels wildtype and mutated mt-ND6 miR-29a-3p target sites, 
and miR-29a-3p perfect match and scrambled site. A: baseline levels without addition of any miRNA mimic. B: Over 
expression of miR-29a. C: Over expression of negative control miRNA mimic. D – E: Expression levels of wildtype and 
mutated miR-125a-5p, miR-152-3p and miR-223-3p target sites. D: baseline levels without addition of any miRNA 
mimic. E: Over expression of miR-125a, miR-152 and miR-223. F: Over expression of negative control miRNA mimic. 
Significance differences found with Students unpaired T-test denoted with stars, **** equals P<0.0001. The 
experiment was performed 3 times in quadruplicate. 
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The miR-29a-3p positive control (miR-29a perfect) behaved as expected with no significant 
difference between the baseline (samples without any mimic) and those with the negative control 
(P>0.05), while the samples with miR-29a mimic showed very significant repression when 
compared with the baseline levels. (P<0.0001). The miR-29a-3p negative control (miR-29a-3p 
scrambled) had no significant difference between the samples with the negative control mimic 
and those with the miR-29a mimic (p>0.05). The controls therefore indicate that the assay can be 
used to determine miRNA driven repression via the measurement of luciferase activity. 
Both the wt and mut miR-29a-3p mt-ND6 vector have a small, but significant decrease between 
the samples with the miR-29a mimic and the baseline (P=0.03 and P=0.02). However there was no 
significant difference between the wt and mut vector with or without 29a over-expression using 
miR-29a mimic. The over expression of the negative miRNA mimic also caused a slight but 
significant decrease in the mut miR-29a-3p vector (P=0.01). The data from the reporter-gene assay 
indicates that the repression observed is not in responsive to the miR-29a mimic. 
For the wt miR-125a-5p mt-ND1 vector the over expression of miR-125a caused a small but 
significant increase of luc2 expression (P=0.01), similar effects were seen for the miR-125a-3p mt-
ND1 mut site, but they were not significant (P>0.05). There was a consistent albeit insignificant 
difference between the wt and mut vector with or without a co-transfected mimic. The data 
indicates that the increase in luciferase activity could be from an indirect effect of miR-125a, but 
unlikely to come from miR-125a regulation on the inserted target site. 
Both the wt and mut the miR-152-3p mt-COX1 vector showed no significant change of the luc2 
activity when co-transfected with the miR-152 mimic (P>0.05). The wt miR-152-3p mt-COX1 vector 
had a small increase in expression when co-transfected with the negative control mimic (P=0.007). 
The data indicates that the miR-152 target site in mt-COX1 does not respond to miR-152 over 
expression, albeit a response to the negative control was unexpected. 
Both the wt and mut miR-223-3p mt-COX1 vector have a small, but highly significant decrease 
between the samples with the miR-223a mimic and those without (P<0.0001 and P<0.0001). 
However there was no significant difference between the wt and mut vector with or without a co-
transfected mimic. Further inspection of the pGL4.13 vector shows a cryptic miR-223-3p target site 
73 nucleotides from the 3’ end of the luc2 gene.  
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Cryptic miR-223-3p site 
 
3’- ACCCCAUAAACUGUUUGACUGU -5’ miR-223-3p 
     | |||:  | |:::|||||| 
5’- CGAGGTGCCTAAAGGACTGACC -3’ luc2 CDS pos. 1559 to 1580 
 
The data indicates that the repression observed may be from the alternative miRNA target site in 
the luc2 gene; however this also means that any effect from the proposed miR-223-3p target site 
in mt-COX1 could be masked by the cryptic site. 
 
4.2 miRNA effect on the glucose stimulated insulin secretion 
 
Figure 17 – glucose stimulated insulin secretion and total protein content: A: The figure shows the insulin levels 
secreted per µg total protein per hour for the over expressed miRNA for a 2 hour stimulation at either 3 or 20mM 
glucose. B: The figure shows the average total protein content of the INS-1e cells the same conditions as A. Negative 
control (NC) 
 
When the 3mM glucose stimulated samples were compared to the negative control, none showed 
significant difference in insulin secretion. Interestingly, the miR-223 over expressed INS-1e cells 
had twice the insulin secretion as the negative controls, but this was only border-line significant 
(P>0.05). With 20mM glucose stimulation the miR-152 and Mir-223 over expressing samples 
showed significant increased insulin secretion (P=0.006 and P=0.002). The protein content were 
also significantly increased at 3mM glucose stimulation for the miR-125a and miR-152 samples, 
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miR-152 also showed significant increase in total protein at 20mM glucose stimulation. The qPCR 
results shows that the miRNA were successfully over expressed compared to the endogenous 
levels with 19.9 ±23 fold for miR-125a, 507 ±566 fold for miR-152 and 4008 ±3017 fold for miR-223 
(Figure 17). Transfection efficiency could not be determined as the fluorescence of the rhodamine 
labeled siRNA had decayed – however earlier in house works showed efficiency of approximately 
70% for this method87. 
 
4.3 miRNA over expression effect on mitochondria 
 
Figure 18 – Effect on mitochondrial membrane potential, mitochondrial mass and amount of radical oxygen species: 
A: TMRM – indicates membrane potential. B: MTDR– indicates mitochondrial mass. C: mitoSOX indicates amount of 
ROS.  
 
As can be seen from Figure 18, The mitochondrial membrane potential as measured with the dye 
TMRM was similar between all three miRNA over expression samples, and the same results is seen 
when the negative control and miR-152 over expression MTDR samples are compared. However 
the total amount of mitochondria as measured with MTDR was much higher in the miR-223 over 
expressed samples. The superoxide production measured with mitoSOX dye also had higher 
intensity in the samples of the miR-223 over expression cells as compared to the negative controls. 
These data suggest that the miR-223 induces an increase in mitochondrial mass and superoxide 
production, but since these data are derived from only one experiment, they must be repeated 
before any firm conclusions can be drawn 
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4.4 Functional annotation of miRNA targets 
Using the functional annotation tool DAVID v. 6.7, biological processes enriched for miRNA targets 
were evaluated using the transcriptome for INS-1 832/13 β-cells collected by Malmgren, S et. al.88 
as the background list. The genelist was prepared from conserved miRNA targets found using the 
Targetscan algorithm v. 7.0 developed by Lewis, B.P et. al76,77. The results were limited to rattus 
norvegicus obtained from functional annotation clustering performed on biological processes 
(GOTERM_BP_FAT). The annotated clusters were limited to those with an enrichment score (-log 
of the geometric mean of the P values of the various processes in the cluster) of ≥5.0, to present 
only the most significant results.  
miR-152-3p 
The target scan algorithm reported 3160 potential target genes of miR-223-3p, of these 626 were 
conserved. Functional annotation analysis was performed using the 626 conserved genes. The 
DAVID algorithm reports 104 different annotation clusters. The seven most significant clusters are 
presented Table 12 (enrichment score of ≥5.0). 
 
Table 12 – Annotation clusters for miR-152-3p: 
Annotation 
Clusterg 
Enrichment score 
(P value range) 
Genes involved 
Positive 
regulation of 
transcription 
21.67 
(4.0*10
-4
 to 1.5*10
-31
) 
ACVR1, ADAM17, ATXN1, BARHL2, BMP3, BRPF1, CALR, CAND1, CBLB, 
CCNA2, CLOCK, CSF1, DNMT1, DYRK1B, E2F3, EGR2, EPAS1, ESR1, ESRRG, 
ETV1, ETV5, GDF6, GTF2H1, HIVEP3, IL6ST, ING2, KIT, KLF4, KLF6, MAF, 
MAFB, MDFIC, MECP2, MED1, MITF, MTF1, NCOA1, NCOR1, NFAT5, NFIX, 
NFYA, NSD1, POU3F2, POU4F2, PPARGC1A, PPARGC1B, PRKAG2, PSEN1, 
RICTOR, RXRA, S1PR1, SIX4, SKP1, SMAD2, SMARCD1, SOX11, TBL1XR1, 
TCF4, TEAD1, TGFA, TGFB2, UBE2D1, WNT1, WNT10B, ZBTB16, ZFPM2 
(n=66) 
Negative 
regulation of 
transcription 
12.58 
(2.8*10
-9
 to 9.0*10
-22
) 
ATXN1, BARHL2, BMP3, CALR, CAND1, CLOCK, EGR2, EPAS1, ESR1, GTF2H1, 
HIVEP1, KCNIP3, KDM6B, KLF4, KLF6, LCOR, MAF, MAFB, MDM4, MECP2, 
MED1, MITF, MTF1, NCOA1, NCOR1, NFAT5, NFIX, NFYA, NSD1, POU3F2, 
POU4F2, PPARGC1A, PPARGC1B, RXRA, RYBP, S1PR1, SIX4, SMAD2, SOX11, 
TBL1XR1, TCF4, TEAD1, TRAK2, TXNIP, WNT10B, ZBTB7A, ZBTB16, ZFHX3, 
ZFPM2 (n=49) 
Response to 
hormone 
stimulus 
8.09 
(1.8*10
-4
 to 8.9*10
-11
) 
ACVR2B, ADAM10, ADAM17, ADCY2, AKAP1, ANK2, ATP2A2, CBLB, CCNA2, 
CHUK, DGCR8, DICER1, DUSP1, EGR2, ERBB3, ESR1, GRIN2A, HSPA4L, IL6ST, 
LDLR, LNPEP, MMP19, NCOA1, PAPPA, PIK3R3, PPARGC1B, PTEN, RXRA, 
SMAD2, SYNJ1, TFRC, TGFB2, TXNIP, UCP3 (n=34) 
Neuronal 
development 
7.38 
(3.0*10
-6
 to 2.5*10
-12
) 
ALCAM, ATP7A, BARHL2, CDK5R1, CNTN4, DYNLL2, EGR2, EMX2, ERBB3, 
ETV1, GAP43, ITGA1, MDGA2, MECP2, NRP1, POU3F2, POU4F2, PPP1R9A, 
PPP1R9B, PSEN1, PTEN, PTPRM, ROBO1, ROBO2, RXRA, S1PR1, SLITRK3, 
STX3, TGFB2, WNT1 (n=30) 
                                                     
g
 The names of the annotation clusters are generated from the processes involved in the specific cluster by the author 
of this thesis. 
Discussion 
55 
 
Apoptosis 6.52 
(0.0016 to 1.2*10
-11
) 
ACVR1, ADAM17, ATP7A, BCL2L2, BCL2L11, CDK5R1, COL2A1, DCUN1D3, 
DEDD, DUSP1, ERBB3, ESR1, GPI, GRID2, GRIN2A, HIPK3, ITGA1, KCNIP3, 
KIT, MAP3K9, MECP2, MITF, MNT, PDIA3, PSEN1, PTEN, ROCK1, RXRA, 
SGMS1, SH3KBP1, SLC2A3, STRADB, TGFA, TGFB2, TXNIP, YWHAB, ZBTB16 
(n=37) 
Cell motion 
and 
migration 
6.31 
(9.5*10-6 to 3.0*10-
10) 
CDK5R1, LYPD3, NRP1, ITGA11, KIT, PTEN, TGFB2, ALCAM, ROBO1, RAB11B, 
ETV1, POU4F2, ROBO2, POU3F2, PTPRM, EGR2, ROCK1, EMX2, BARHL2, 
ITGA1, SIX4, ELMO1, PSEN1, ITGA5, ADAM17, GAP43, ACVR1 (n=27) 
Angiogenesis 5.42  
(9.9*10
-6
 to 1.5*10
-6
) 
NRP1, EPAS1, EFNB2, DICER1, PTEN, PNPLA6, TGFB2, ATP7A, GPI, S1PR1, 
MEOX2, PSEN1, ROBO1, TGFA, ZFPM2, C1GALT1, ACVR1 
(n=17) 
 
miR-223-3p 
The targetscan algorithm reported 2596 potential target genes of miR-223-3p, of these 266 were 
conserved. Functional annotation analysis was performed using the 266 conserved genes. The 
DAVID algorithm reports 46 different annotation clusters. The most significant clusters are 
presented in Table 13 (enrichment score of ≥5.0). 
 
Table 13 – Annotation clusters for miR-223-3p: 
Annotation 
Clusterh 
Enrichment score 
(P value range) 
Genes involved 
Regulation of 
transcription 
8.40 
(0.0017 to 3.6*10
-13
) 
AEBP2, CARM1, CBX5, CDYL, CNOT2, COPS2, E2F1, EBF3, ELF2, ELK4, 
FOXO3, FOXP1, FOXP4, HDAC4, HEY2, HHEX, HLF, LIF, MAFB, MEF2C, MGA, 
MYBL1, NFAT5, NFIA, NFIB, NLRP3, NRF1, PAX6, PGR, PKNOX1, POU2F1, 
PURA, PURB, RAB10, RBPJ, RNF4, RORB, SMARCD1, SNAPC3, SOX11, SOX6, 
SP3, SSRP1, TGFBR3, TWIST1, WASL, ZBTB10, ZEB1, ZFHX3 (n=49) 
 
4.5 Mitochondrial reporter gene assay 
The preliminary results show that the change of the Isoleucine codon from ATA to ATT retain 
cytosolic expression, but does appear to induce a general decrease in the activity of the luc2uni 
gene, for both the D-loop and Sv40 promoter Figure 19 A. The change of the tryptophan codons 
from TGG to TGA appears to have had the desired effect of inhibiting cytosolic mediated activity of 
luc2mito. The activity of luc2mito remains slightly above background, see Figure 19 B, indicating 
some low level translation does occur – potentially in the mitochondria. Addition of TFAM and 
PGC1a expression vectors did appear to change the activity of the D-loop promoter constructs 
slightly (Figure 20). 
 
                                                     
h
 The names of the annotation clusters are generated from the processes involved in the specific cluster by the author 
of this thesis. 
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Figure 19 – luciferase expression levels after mutations: A: shows the relative luciferase activity of the mutated 
luciferase gene luc2
uni
 relative to luc2. B: The raw data depicting the expression of the mitochondrial only translatable 
luciferase gene luc2
mito
 or luc2 from the D-loop or Sv40 promoter as well as from promoterless constructs. The 
transfections were done with or without either mitochondrial transcription factor A (TFAM) or Peroxisome ppar 
gamma co-activator 1 alpha (PGC1a). The experiment was performed once in triplicates. 
 
Figure 20 – Expression response to co-transfection of TFAM or PGC1A: Relative expression levels from the D-loop or 
Sv40 promoter of the three luciferase variants in response to co-expression of A: mitochondrial transcription factor A 
(TFAM) or B: Peroxisome ppar gamma co-activator 1 alpha (PGC1a).  Luc2 represent the wildtype luciferase gene, 
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luc2
uni
 is translatable in both the mitochondria and cytosol and luc2
mito
 which can only be translated in the 
mitochondria. The experiment was performed once in triplicates.  
 
4.5.1 A side note regarding cloning of the D-loop vectors 
During the course of this experiment an issue with the amplification of the D-loops vectors was 
experienced. The D-loop insert was cloned into the pGL4.10 vector and used to transform 
chemical competent E. coli cells, which were then spread on an agar plate containing 1µg/ml 
ampicillin. After incubation for 18hrs at 37°C the agar plates contained many small colonies of 
various size as well as a few normal coloniesi. After isolation and restreaking the normal colonies 
grew as expected but was found to contain the pGL4.10 vector without the insert. The small 
colonies were initially not tested as they were thought to be an issue of contamination of either 
the competent cells or the D-loop. The cloning was redone with new stock of competent cells and 
from a new PCR amplification of the D-loop. The problem with small colonies persisted and this 
made it clear that the issue was connected to vectors containing a D-loop insert. The small 
colonies were then restreaked from the original agar plate but several attempts to grow the 
colonies failed. Research into the literature showed that the full length human mitochondrial 
genome exerted a toxic phenotype, incompatible with growth in E. coli as observed by Drouin 
(1980)89, Mita and colleagues90 (1988) and Bigger and colleagues91 (2011). The toxic sequence was 
mapped to a position between the 15591 and 16053 (D-loop pos. 16005 to 601), albeit it was 
found that the toxic phenotype was relieved by specific mutations in the tRNAThr gene (pos. 15888 
to 15593) although the mechanism is as yet uncovered. In this experiment however successful 
growth of E. coli with a D-loop vector was obtained if incubated at room temperature, and not at 
30°C as reported by the studies of Mita and Bigger. However the growth rate was severely 
impaired when compared to other transformants at the same temperature. 
 
 
  
                                                     
i
 Appearance and size similar to colonies containing pGL4.10 with no insert 
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5 Discussion 
5.1 Detection and testing of mitochondrial miRNA target sites 
The bioinformatic approach gave 187 hits from 37 miRNA, four of these were chosen for further 
evaluation. The miR-29a over expression only caused a slight repression of luc2 activity for the wt 
and mut target site compared to the negative control, However as there were no significant 
difference between the wt and mut mt-ND6 target site, the regulation is not believed to be 
mediated miR-29a-3p interactions at the tested target site, but by other effects on the INS-1e 
cells. The data therefore suggest that the mt-ND6 site is unlikely to be regulated by miR-29a-3p, 
atleast when tested with a cytosolic reporter gene assay. This is supported by another RUC 
bachelor project which evaluated the same miR-29a-3p target site in mt-ND6, and was unable to 
detect any regulation by miR-29a over expression as well92.  
The miR-125a-5p target in mt-ND1 interestingly showed a slight repression of luc2 activity from 
the wt vector when compared to the mut target site vector in all tested conditions, while the 
difference was not significant a clear trend can be seen. The difference is not mediated by 
endogen miR-125a-5p activity on the target site as over expression of the miR-125a mimic caused 
an increase in the luciferase activity from both vectors. Therefore the conclusion is that the mt-
ND1 target site is not regulated by miR-125a-5p binding and the wt target site is repression 
compared to the mut target site is mediated by an unknown mechanism. The increase in luciferase 
activity in response to miR-125a over expression might be from increased in the total protein of 
the INS-1e cells, as miR-125a is correlated with increased protein content as seen for the protein 
measurement in the GSIS assay.  
The miR-152 mt-cox1 vectors interestingly only showed a response for the wt vector with over 
expression of the negative control mimic. The response to the negative control mimic cannot 
readily be explained, but the effect is most likely connected to the mt-COX1 site insert as the mut 
vector shows no response although the mRIDIAN negative control has no apparent alignment of 
the to the wt or mut target site. While the effect of the negative control cannot be readily 
explained, miR-152-3p can be concluded not to interact with the proposed target site in mt-COX1.  
MiR-223-3p target in mt-COX1 was also tested and showed significant repression of the luciferase 
activity to only 0.5 fold compared to the negative control at miR-223 over expression. The effect 
interestingly did not differ between wt and mut vector – Investigation into this issue revealed that 
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Luc2 contains a potential miR-223-3p target site. It is therefore my hypothesis that this cryptic 
miR-223-3P target site in luc2 is the reason for decreased luciferase activity.  The presence of the 
cryptic miR-223-3p target site however may masks effect of miR-223-3o on the inserted mt-COX1 
site. So no conclusion regarding the effect of miR-223 on the mt-COX1 site can be deduced from 
the results. The test could remedied by inducing silent point mutations to the cryptic miR-223 site 
in order to remove the interference, or use another reporter gene altogether.  
None of the tested targets could be verified for direct miRNA induced effects by the reporter gene 
assay. There  is little doubt to the validity of the result as the reporter gene assay is considered the 
golden standard for validation of mRNA-miRNA interactions93 and the results from the miR-29a-3 
perfect and scrambled target site controls behaved as expected. However as the reporter gene is 
both transcribed and translated in the cytosol proper reflection intra-mitochondrial effect cannot 
be assumed, and the cannot be used for validation, but only used as a guideline to test the 
strength of the miRNA-mRNA basepairing. The mitochondria specific reporter gene assay was 
unfortunately not finished within the timeframe of the thesis, preventing a final conclusion of the 
feasibility of this bioinformatic approach. However only four of the proposed targets sites were 
tested, and miR-29a and miR-223 exhibit a mitochondrial phenotype as described later in section 
5.2. The MiR-223 mt-COX1 target site have a 7nt long perfect base pairing of the seed region to 
the mt-COX1 site and generally good complementarily to the remainder of the miRNA sequence. 
So miR-223 and its target site it is still a prime candidate, and should be retested without 
interference from the cryptic miRNA target site in luc2, preferably in the mitochondrial selective 
reporter gene assay. 
5.2 Mitochondrial derived phenotypes 
Over expression of miR-125a, miR-152 and miR-223 were tested for their effect on GSIS. GSIS and 
the mitochondria are closely linked14-16 so GSIS were used as an indirect measurement for general 
mitochondrial function in the INS-1e cells. miR-29a were not tested for GSIS effects as repression 
of GSIS by miR-29a mimics and GSIS rescue by miR-29a depletion has previously been tested and 
observed by Bagge A and collegues82 within the department. Further testing of miR-29a on 
mitochondrial functions was performed by Louise Torp Dalgaard and other members of the 
Diabetes and β-cell biology Group – unpublished data. MiR-29a over expression was found to 
decrease mitochondrial mass and membrane potential. MiR-29a therefore induces a 
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mitochondrial derived phenotype, although the mechanism behind the mitochondrial changes is 
unknown. 
Effects of miR-125a, miR-152 and miR-223 over expression on total protein mass were measured 
as well and used to normalize the GSIS assay. The nucleofection successfully over expressed miR-
125a ~20fold in the INS-1e cells. 72hrs post nucleofection, miR-125a over expression showed no 
significant effect on GSIS of INS-1e cells at 3 and 20mM glucose stimulation, except for a small but 
significant increase in the total protein content of the 3mM glucose stimulated cells when 
compared to the negative control. A similar, but insignificant increase in cell mass however was 
also seen in INS-1e cells stimulated with 20mM glucose. MiR-125a may have important effects for 
β-cell development, due to its upregulation in the late stage of differentation64, but because the 
lack of impact of miR-125 over expression on the GSIS no further analysis was performed.  
Nucleofection with miR-152 successfully over expressed ~500 fold in the INS-1e cells where it 
caused a significant increase in the insulin secretion at 20mM glucose coupled to very significant 
increase in the protein content of the cells with 60% and 67% at 3 and 20mM glucose 
respecitively. The increase in GSIS does not readily support a hypothesis of intra-mitochondrial 
gene regulation, as canonical miRNA regulation decrease the expression of the target genes41, 
albeit the lack of knowledge regarding mitomiRs effect in the mitochondria means that non-
canonical regulation cannot be ruled out. If the GSIS were upregulated due to mitochondrial 
effects of miR-152 then increased mitochondrial function would be expected. However intra-
mitochondrial effects on the GSIS are not supported by the fact that the mass, membrane 
potential and superoxide production of the mitochondria were unchanged in response to miR-152 
over expression. The GSIS measurements are also in direct contrast with the findings by Eliasson 
and collegues84 which found that miR-152 over expression decreased GSIS and total insulin at 
16.7mM glucose in INS-1 832/13 cells. However Melkman-Zehavi and colleagues showed that the 
closely related member of the miR-152/miR-148 family, miR-148a increase insulin promoter 
activity in the mice derived GSIS sensitive MIN6 cell culture94 and insulin mRNA is decreased in 
primary cultures of murine islet of langerhans treated with anti-miR-148a95. 
 
 
 
miR-152a-3p: 5’- UCAGUGCAUGACAGAACUUGG -3’ 
                 ||||||||  ||||||||| | 
miR-148a-3p: 5’- UCAGUGCACUACAGAACUUUGU -3’ 
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The proposed insulin stimulus is the miR-148a-3p direct transcriptional repression of Sox6 and 
bhlhe22, two insulin promoter repressors. Interestingly these two targets were not reported by 
the targetscan algorithm – although the presence of a seed pairing region can be confirmed by 
visual inspection of the Sox6 and bhlhe22 CDS.  Melkman-Zehavi and colleagues observations do 
not address the effect of miR-148a on GSIS or total insulin content directly, but the total insulin is 
likely to be increased in response to increased amount of insulin transcripts. DAVID prediction for 
miR-152-3p was positive regulation of transcription (enrichment score 21.67), meaning that 
biosynthesis otherwise might be decreased, although interestingly the second most significant 
process were negative regulation of transcription (enrichment score 12.58). Melkman-Zehavi and 
colleagues observations together with the predictions from DAVID, might explain the observed 
differences in GSIS between this study and Eliasson and colleagues.  
These data suggest that miR-152 may increase the GSIS relative to the total protein content, but 
not to the total insulin content. The method used for GSIS normalization by Eliasson and 
colleagues is unknown. The normalization is however important as normalization to the total 
insulin would potentially show decreased GSIS because of increased insulin levels, whereas 
normalization to total protein content would show an increased GSIS. At this point this is only 
speculations, but it would be prudent to measure the insulin content of the total protein samples 
from the assay for equal comparison. One caveat is that total protein increased in the miR-152 
samples compared to the negative control, this does not agree with a hypothesis of general 
decrease in transcription. One possibly hypothesis might be that miR-152 increase in total protein, 
is a indirect effect of increased cellular survival during nucleofection recovery. The increased ratio 
of surviving seeded cells compared to the negative control is then reflected in a general increased 
cell mass. DAVID predicted miR-152-3p targets in both anti- and pro-apoptotic processes 
(enrichment score 6.52). The DAVID predictions regarding regulated biological processes cannot 
however be used as definitive arguments the same genes might appear in different and even 
opposite biological processes, as seen from the two most significant annotation clusters. The 
results however do not support a mitochondrial phenotype from miR-152 over expression, as the 
increased GSIS may be explained by extra-mitochondrial effects.  
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miR-223 was successfully over expressed in INS-1e with nucleofection, were it caused a significant 
two-fold increase in the insulin secretion at 20mM glucose, a clear trend for an  increase of insulin 
secretion at 3mM was also observed, albeit significance could not be established (P=0.052). Unlike 
miR-152 the increase in the insulin secretion were not coupled to an increase in total protein 
content, however the mitochondrial mass as well as superoxide production were increased 
considerably. GSIS is intimately linked to mitochondrial function and these results suggest an 
increase in the insulin secretion might be related to mitochondrial effects of miR-223. So miR-223 
induces a very interesting mitochondrial phenotype. The DAVID annotation tool showed that miR-
223a-3p very highly enriched for targets involved in transcriptional processes, and one of the 
targets were Sox6. Meaning that miR-223a-3p may influence the relative insulin biosynthesis like 
described for miR-152/148. Bai and colleagues also showed evidence that miR-223-3p together 
with miR-146 increased insulin secretion in chick β-cells. The mechanism was believed to be due to 
an observed increase in intracellular concentration of Ca2+ and Ca2+ mediated insulin efflux. Their 
hypothesis was that the Ca2+ increase were related to a miR-223/146 mediated decrease in the 
nuclear encoded Wnt5A protein levels86. These finding however do not explain the apparent effect 
of miR-223 over expression on the mitochondria. MiR-223 has previously been found to decrease 
translocation to the hepatic mitochondria, relative to the cytosol of Streptozotocin induced 
diabetic mice, indicating that miR-223 location to the mitochondria might be actively62 regulated, 
although the mechanism remains unknown.  
While miR-29a and miR-223 over expression do exhibit a mitochondrial phenotype, these data 
alone do not prove any miRNA mediated intra-mitochondrial regulation. However it would be very 
interesting to measure the mRNA and protein levels of the mitochondrial genes, and compare the 
relative levels to the negative control. Unlike nucleus encoded genes whose transcription are 
subject to regulation by several factors the polycistronic transcription in the mitochondria is 
initiated and controlled from the D-loop only. This means that all mRNA from the same strand 
should be expected to be expressed at the same relative levels unless subjected to regulation 
within the mitochondria, and as such can be used as a marker for mitochondrial effects of the miR-
223. 
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5.3 Mitochondria selective reporter gene assay  
MitomiRs are a relatively new discovery, and has as yet a limited impact on the research 
community, and currently there are to the best of my knowledge no assay developed for the 
testing of the intra-mitochondrial effects on a given miRNA target site. This problem was 
addressed by making a reporter gene assay based on codon differences from the mitochondria 
and the universal genetic code. This allowed the cloning of constructs whose transcript could only 
be translated in the mitochondrial department. The reporter gene Luc2 contains an isoleucine 
codon that would be translated as a methione in the mitochondria, so first this codon was 
changed to a conserved isoleucine codon. While the mutation was a success it induced a small 
overall repression of the activity of the luc2uni gene, the repression is believed to be due to codon 
bias96 within the INS-1e cells, but are not confirmed. There are also 2 tryptophan codons within 
the luc2 gene that was changed in such a way that they encode stop codons in the cytosol, but still 
encodes tryptophan within the mitochondria – these were used to convert luc2uni into a 
mitochondrial only translatable luc2 gene (luc2mito). The cloning of luc2mito was a success and the 
luciferase activity dropped to levels near zero, but still slightly background when transcribed from 
the pGL4.13[Sv40, luc2mito] and pGL4.10[D-loop, luc2mito]. The low level activity from luc2mito might 
be from mitochondrial derived luciferase protein as the pGL4.10 promoterless vector exhibited no 
luciferase activity. The result is therefore encouraging as the luc2mito, but it is puzzling that there is 
no difference between the cytosolic promoter construct pgl4.13[Sv40, luc2mito] and the 
mitochondrial promoter construct pgl4.10[D-loop, luc2mito]. However increased amount of sample 
material could be tested to make small differences more apparent97. Nonetheless the question 
then arise itself as to where is the mRNA transcribed and where is it translated? Overviews of 
possible pathways are shown in Figure 21. 
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Figure 21 – Translational pathways for Luc2
mito
: The figure shows the possibly pathways that would lead to translation 
of the mitochondrial only luciferase gene Luc2
mito
. 
 
The mRNA produced from luc2mito should not be translated in the cytosol, but TGA codons are 
known to be bypassed by a rare occurrence known as ribosomal readthrough98. The luc2uni 
experiments showed that luciferase activity was several fold higher with the Sv40 promoter, 
indicating that the mRNA transcribed are also higher, ribosomal readthrough could therefore be 
expected to be relatively higher for pGL4.13[Sv40, luc2mito]. Ribosomal readthrough is dependent 
on a TGA CT(A) motif, which is present in only one of the two stop codons. However as the 
mechanism still unknown and the stop codons are only 27nt apart crosstalk between the codons 
cannot be ruled out making ribosomal readthrough is a potential source of luciferase activity. The 
ribosomal readthrough could be indirectly tested by changing some of the 20 arginine codons in 
the Luc2mito variant into either AGG or AGAj, so that mitochondrial translation is inhibited as well. 
                                                     
j
 AGG and AGA Encodes arginine in the cytosol, but a stop codon in the mitochondria. 
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This new luc2 (Luc2stop) variant would be universally untranslatable, and return to background 
levels would indicate that the translation from Luc2mito is likely mitochondrial dependent. Another 
possibility is that the mRNA is transcribed in the cytosol and then enters the mitochondria to be 
translated, but the transport or translation becomes saturated leading to equal luciferase activity 
regardless of the increased transcription from the Sv40 promoter. Both transcription and 
translation could also happen inside the mitochondria, but then the Sv40 promoter would exhibit 
the same activity as the D-loop within the mitochondria. Equal activities of both promoters within 
the mitochondria is however considered unlikely, as the addition of mitochondrial transcription 
factor TFAM or PGC1a did not increase the luciferase activity from the D-loop vector as otherwise 
expected45,46. Mitochondrial transcription has also been shown to be dependent on the H-strand 
and L-strand promoter, as mutations in these sites completely ablated transcription of the 
respective strands99. Saturation of the mitochondrial translation however is a possibility. The 
luc2mito design was based on mitochondrial codon composition, but the mitochondrial mRNA 
processing and translation was not addressed. The Mitochondrial genome is transcribed as a 
polycistronic transcript and transcription is terminated by reentry into the D-loop region, but the 
processing to mRNA is mediated by restriction directed by tRNAs or tRNA like secondary 
structures49. No sequence was appended to facilitate RNA processing of the vector transcript and 
the luc2mito would therefore have an unusually long 3’ UTR compared to native mitochondrial 
mRNA. The effect of extension of the 3’UTR for translation termination is unknown, but a 
processing sequence should be appended after Luc2mito. The long 3’ UTR might also interfere with 
translation termination or ribosomal release as the ribosomes ends transcription very close to the 
3’ end of the transcript. Currently none of the options can be ruled out without further testing. 
One major limitation of this assay was the delivery of the plasmids to the mitochondria. 
Lipofectamine 2000 were used for the transfection, but  lipofectamine 2000 only facilitate the 
movement of DNA across the cell membrane, thus the actual amount of plasmids entering the 
mitochondria must be assumed to be relatively low. Transfection of the mitochondria into intact 
cell is notoriously difficult, as the transfection method needs to facilitate movement across the cell 
membrane as well as the two mitochondrial membranes. So far no commercially kit is available to 
the best of my knowledge. Ssuccess of mitochondrial transfection to whole cells has been done 
with biolistic/gene gun, and more sophisticated approaches using mitotropic liposomes, amphillic 
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carries or phusion-proteins with both DNA binding and mitochondria translocating domains100. 
However nucleofection makes pores across dielectric membranes, including the nucleus and has 
been used extensively to transfect isolated mitochondria. Nucleofection could therefore  
theoretically also allow for transfection in whole cells and plausibly increase mitochondrial 
transfection efficiency, making mitochondrial luciferase expression more pronounced.  
A point of concern was if the strength of the lysis buffer was sufficient for lysis of the 
mitochondrial membrane facilitating proper mix of luciferin substrate and the luciferase enzyme. 
The lysis buffer used consisted of 100 mM potassium phosphate at pH 7.8, with 0.2% Triton X-100, 
however Gurtubay and colleagues101 showed that triton x-100 concentration as low 0.05% initiates 
mitochondrial membrane disruption and full membrane disintegration at 0.1% in pure 
mitochondrial preparations. The luciferase assay used (Thermo Fischer scientific) is compatible 
with stronger lysis buffers as long as reducing agents are avoided, so a stronger buffer could be 
used to ensure full mitochondrial membrane disruption. 
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6 Conclusion 
The in silico approach to detect mitochondrial miRNA target sites produced 187 targets for 37 
miRNAs, four targets, one for miR-29a-3p, miR-125a-5p, miR-152-3p and miR-223-3p were tested 
with a luciferase reporter gene assay. The miRNA target site for miR-29a-3p, miR-125a-5p and 
miR-152-3p showed no regulation of the tested target sites. The effect of miR-223-3p on the 
tested target site could not be evaluated due to a cryptic miR-223-3p target site present in luc2. 
The feasibility of the applied bioinformatics approach cannot be discarded as only a few potential 
miRNA were tested, and the reporter gene assay is unsuitable for mitomiR validation.  
Over expression of miR-125a, miR-152 and miR-223 in INS-1e cells were performed to test indirect 
effects on mitochondrial functions in the INS-1e cells. MiR-125a over expression had no effect in 
regards to GSIS, but miR-152 and miR-223 over expression showed an increase in the GSIS at 
20mM glucose, and miR-223 an increase at 3mM glucose as well. The increased GSIS for miR-152 
could not be correlated to changes in mitochondrial mass or membrane potential, and is believed 
to be mediated by increased biosynthesis of insulin. MiR-223 showed increased mitochondrial 
mass and superoxide production, as well as increased GSIS. The data suggest that miR-223 may 
play an important role β-cell function, potentially by intra-mitochondrial regulation, but further 
experimentation is needed before any final conclusion can be made. 
The mitochondrial expression assay shows promising results, as the mitochondrial Luc2mito gene 
produced luciferase activity, albeit at low levels. However the luciferase activity did not change in 
response to expression from the mitochondrial D-loop or the cytosolic Sv40 promoter putting 
doubt to the site of translation and the assay suffered from low luciferase activity. Lack of specific 
controls prevented definitive confirmation regarding the exact site of translation and the assay is 
therefore in its current form insufficient for its intended purpose of measuring intra-mitochondrial 
miRNA regulation. These limitations need to be overcome before the validity of the mitochondrial 
expression assay can be confirmed and potentially be used in practice. 
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7 Perspectives 
T2DM has reached epidemic proportions, and have severe socioeconomic consequences, but 
prevention of T2DM is possibly if detected early, unfortunately the current screening procedures 
have limited prognostic value, and the treatment relies on patient compliance to a regime of 
“undesirable” lifestyle interventions. However If the cause of the β-cell dysfunction could be 
uncovered, better screening, and potentially a pharmaceutical treatment against the underlying 
cause could be developed. The possibly implication of mitochondrial miRNA regulation for the 
pathogenic processes requires the development of methods suitable for investigation of specific 
miRNA interactions. The mitochondrial selective reporter gene assay could potentially be a 
method for testing possible miRNA target sites, or other regulatory DNA sequences within the 
mitochondria, although the limitations mentioned in the discussion needs to be addressed. The 
miR-223 targets found with the bioinformatic approach, would be prime candidates for testing 
due to the impact this miRNA had on the mitochondrial phenotypes.  
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Mitochondrial miRNA targets sites 
The cell containing target site tested in this thesis are dark grey, other sites for the same mircoRNA have a 
their cells in a lighter shade of grey.  (A or B) refers to the detection of the miRNA within mitochondrial 
preparations by PhD student Julian Geiger. 
 
miRNA 
miRNA 
start (5') 
Area of Hit/miRNA 
basepairing 
Hsa mitochondria 
Annealed length 
Basepairing 
overview Target gene 
 let-7b-5p  3 10970 10964 7 ||||||| ND4 
 let-7b-5p  2 11047 11041 7 ||||||| ND4 
 let-7b-5p  2 13586 13580 7 ||||||| ND5 
 let-7b-5p  3 13856 13850 7 ||||||| ND5 
 let-7b-5p  2 11384 11379 6 |||||| ND4 
 let-7b-5p  1 10548 10543 6 |||||| ND4L 
 let-7b-5p  2 13438 13433 6 |||||| ND5 
 let-7b-5p  3 13793 13788 6 |||||| ND5 
 let-7b-5p  1 13849 13844 6 |||||| ND5 
 let-7b-5p  1 14070 14065 6 |||||| ND5 
 let-7d-3p  2 8041 8035 7 ||||||| COX2 
 let-7g-5p  3 10970 10964 7 ||||||| ND4 
 let-7g-5p  2 11047 11041 7 ||||||| ND4 
 let-7g-5p  2 13586 13580 7 ||||||| ND5 
 let-7g-5p  3 13856 13850 7 ||||||| ND5 
 let-7g-5p  2 11384 11379 6 |||||| ND4 
 let-7g-5p  1 10548 10543 6 |||||| ND4L 
 let-7g-5p  2 13438 13433 6 |||||| ND5 
 let-7g-5p  3 13793 13788 6 |||||| ND5 
 let-7g-5p  1 13849 13844 6 |||||| ND5 
 let-7g-5p  1 14070 14065 6 |||||| ND5 
 miR-125a-5p  3 3935 3928 8 |||||||| ND1 
 miR-125a-5p  2 3666 3661 6 |||||| ND1 
 miR-133a-5p  2 11177 11172 6 |||||| ND4 
 miR-136-5p  1 5986 5981 6 |||||| COX1 
 miR-136-5p  1 7383 7378 6 |||||| COX1 
 miR-136-5p  2 14377 14382 6 |||||| ND6 
 miR-152-3p  1 7091 7081 11 |||||| |||| COX1 
 miR-152-3p  1 5904 5899 6 |||||| COX1 
 miR-155-5p  2 4206 4199 8 |||||||| ND1 
 miR-155-5p  2 13476 13469 8 |||||||| ND5 
 miR-155-5p  3 12617 12611 7 ||||||| ND5 
 miR-155-5p  3 13313 13307 7 ||||||| ND5 
 miR-155-5p  2 15098 15093 6 |||||| CYTB 
 
Appendix 
79 
 
miR-155-5p  1 15473 15468 6 |||||| CYTB 
 miR-155-5p  3 4248 4243 6 |||||| ND1 
 miR-155-5p  1 12030 12025 6 |||||| ND4 
 miR-155-5p  1 12680 12675 6 |||||| ND5 
 miR-155-5p  1 13667 13662 6 |||||| ND5 
 miR-155-5p  1 13700 13695 6 |||||| ND5 
 miR-183-5p  1 6431 6425 7 ||||||| COX1 
 miR-183-5p  2 7069 7064 6 |||||| COX1 
 miR-183-5p  1 3465 3460 6 |||||| ND1 
 miR-183-5p  2 3838 3833 6 |||||| ND1 
 miR-183-5p  1 3855 3850 6 |||||| ND1 
 miR-183-5p  2 4639 4634 6 |||||| ND2 
 miR-199a-3p  3 12354 12344 11 |||||| |||| ND5 
 miR-199a-3p  3 12589 12582 8 |||||||| ND5 
 miR-199a-3p  3 13424 13418 7 ||||||| ND5 
 miR-199a-3p  3 6312 6307 6 |||||| COX1 
 miR-199a-3p  3 6532 6527 6 |||||| COX1 
 miR-199a-3p  3 6687 6682 6 |||||| COX1 
 miR-199a-3p  3 12977 12972 6 |||||| ND5 
 miR-200b-3p  2 6865 6860 6 |||||| COX1 B 
miR-200b-3p  1 6977 6972 6 |||||| COX1 B 
miR-200b-3p  1 9617 9612 6 |||||| COX3 B 
miR-200b-3p  2 14579 14584 6 |||||| ND6 B 
miR-200c-3p  2 6865 6860 6 |||||| COX1 
 miR-200c-3p  1 6977 6972 6 |||||| COX1 
 miR-200c-3p  1 9617 9612 6 |||||| COX3 
 miR-200c-3p  2 14579 14584 6 |||||| ND6 
 miR-20b-5p  2 7193 7188 6 |||||| COX1 
 miR-20b-5p  2 15719 15714 6 |||||| CYTB 
 miR-20b-5p  2 13820 13815 6 |||||| ND5 
 miR-223-3p  1 12536 12529 8 |||||||| ND5 A/B 
miR-223-3p  2 6147 6141 7 ||||||| COX1 A/B 
miR-223-3p  1 10804 10798 7 ||||||| ND4 A/B 
miR-223-3p  2 9125 9120 6 |||||| ATP6 A/B 
miR-223-3p  1 4844 4839 6 |||||| ND2 A/B 
miR-223-3p  1 11521 11516 6 |||||| ND4 A/B 
miR-223-3p  1 13593 13588 6 |||||| ND5 A/B 
miR-23b-5p  1 6436 6431 6 |||||| COX1 
 miR-23b-5p  2 7367 7362 6 |||||| COX1 
 miR-23b-5p  2 7427 7422 6 |||||| COX1 
 miR-23b-5p  1 9246 9241 6 |||||| COX3 
 miR-23b-5p  1 4990 4985 6 |||||| ND2 
 miR-23b-5p  1 5436 5431 6 |||||| ND2 
 
Appendix 
80 
 
miR-24-3p  1 12544 12536 9 ||||||||| ND5 A 
miR-24-3p  2 6926 6920 7 ||||||| COX1 A 
miR-24-3p  2 9506 9500 7 ||||||| COX3 A 
miR-24-3p  2 13560 13554 7 ||||||| ND5 A 
miR-24-3p  3 6730 6725 6 |||||| COX1 A 
miR-24-3p  3 9646 9641 6 |||||| COX3 A 
miR-24-3p  1 13973 13968 6 |||||| ND5 A 
miR-27a-5p  3 6006 6000 7 ||||||| COX1 
 miR-27a-5p  3 15710 15704 7 ||||||| CYTB 
 miR-27a-5p  1 8993 8988 6 |||||| ATP6 
 miR-27a-5p  3 9184 9179 6 |||||| ATP6 
 miR-27a-5p  1 6928 6923 6 |||||| COX1 
 miR-27a-5p  1 9280 9275 6 |||||| COX3 
 miR-27a-5p  1 15321 15316 6 |||||| CYTB 
 miR-27a-5p  2 15556 15551 6 |||||| CYTB 
 miR-27a-5p  3 4926 4921 6 |||||| ND2 
 miR-27a-5p  2 11417 11412 6 |||||| ND4 
 miR-27a-5p  2 11429 11424 6 |||||| ND4 
 miR-27a-5p  1 11646 11641 6 |||||| ND4 
 miR-27a-5p  1 11973 11968 6 |||||| ND4 
 miR-27a-5p  1 12944 12939 6 |||||| ND5 
 miR-27a-5p  1 13073 13068 6 |||||| ND5 
 miR-27a-5p  1 13562 13557 6 |||||| ND5 
 miR-27a-5p  1 13808 13803 6 |||||| ND5 
 miR-27a-5p  1 13841 13836 6 |||||| ND5 
 miR-29a-3p  2 14363 14369 7 ||||||| ND6 A 
miR-29a-3p  3 14249 14254 6 |||||| ND6 A 
miR-29c-3p  2 14363 14369 7 ||||||| ND6 
 miR-29c-3p  3 14249 14254 6 |||||| ND6 
 miR-30c-1-3p  2 15387 15382 6 |||||| CYTB A 
miR-30c-1-3p  3 15857 15852 6 |||||| CYTB A 
miR-30c-1-3p  3 11063 11058 6 |||||| ND4 A 
miR-30c-1-3p  2 11818 11813 6 |||||| ND4 A 
miR-331-5p  1 13309 13299 11 |||||| |||| ND5 
 miR-331-5p  3 13437 13429 9 ||||||||| ND5 
 miR-331-5p  1 15227 15222 6 |||||| CYTB 
 miR-331-5p  1 3607 3602 6 |||||| ND1 
 miR-331-5p  3 13488 13483 6 |||||| ND5 
 miR-331-5p  2 13794 13789 6 |||||| ND5 
 miR-331-5p  2 13857 13852 6 |||||| ND5 
 miR-331-5p  2 14026 14021 6 |||||| ND5 
 miR-342-5p  1 15541 15535 7 ||||||| CYTB 
 miR-342-5p  1 13030 13024 7 ||||||| ND5 
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miR-342-5p  2 14817 14812 6 |||||| CYTB 
 miR-342-5p  1 15530 15525 6 |||||| CYTB 
 miR-342-5p  1 10983 10978 6 |||||| ND4 
 miR-342-5p  1 11540 11535 6 |||||| ND4 
 miR-342-5p  2 12971 12966 6 |||||| ND5 
 miR-342-5p  2 13061 13056 6 |||||| ND5 
 miR-34a-5p  1 6429 6424 6 |||||| COX1 
 miR-34a-5p  3 3706 3701 6 |||||| ND1 
 miR-34a-5p  1 3837 3832 6 |||||| ND1 
 miR-34c-5p  2 11308 11302 7 ||||||| ND4 
 miR-34c-5p  1 14868 14863 6 |||||| CYTB 
 miR-34c-5p  1 15027 15022 6 |||||| CYTB 
 miR-34c-5p  1 11589 11584 6 |||||| ND4 
 miR-34c-5p  1 11745 11740 6 |||||| ND4 
 miR-361-5p  1 8701 8696 6 |||||| ATP6 
 miR-361-5p  3 6462 6457 6 |||||| COX1 
 miR-361-5p  3 6612 6605 8 |||||||| COX1 
 miR-379-3p  1 6716 6711 6 |||||| COX1 
 miR-379-3p  1 7436 7431 6 |||||| COX1 
 miR-379-3p  2 9891 9886 6 |||||| COX3 
 miR-379-3p  2 11726 11721 6 |||||| ND4 
 miR-379-3p  1 11989 11984 6 |||||| ND4 
 miR-382-5p  2 9846 9841 6 |||||| COX3 
 miR-382-5p  1 14845 14840 6 |||||| CYTB 
 miR-382-5p  3 3404 3399 6 |||||| ND1 
 miR-382-5p  1 4185 4180 6 |||||| ND1 
 miR-382-5p  2 5131 5126 6 |||||| ND2 
 miR-382-5p  2 11340 11333 8 |||||||| ND4 
 miR-410-5p  2 15771 15765 7 ||||||| CYTB 
 miR-410-5p  1 10905 10899 7 ||||||| ND4 
 miR-410-5p  1 12746 12740 7 ||||||| ND5 
 miR-410-5p  1 13385 13379 7 ||||||| ND5 
 miR-410-5p  2 8647 8642 6 |||||| ATP6 
 miR-410-5p  3 9201 9196 6 |||||| ATP6 
 miR-410-5p  2 9672 9667 6 |||||| COX3 
 miR-410-5p  2 15368 15363 6 |||||| CYTB 
 miR-410-5p  1 3323 3318 6 |||||| ND1 
 miR-410-5p  2 3449 3444 6 |||||| ND1 
 miR-410-5p  1 3599 3594 6 |||||| ND1 
 miR-410-5p  1 3605 3600 6 |||||| ND1 
 miR-410-5p  2 5061 5056 6 |||||| ND2 
 miR-410-5p  2 10843 10838 6 |||||| ND4 
 miR-410-5p  1 10925 10920 6 |||||| ND4 
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miR-410-5p  2 10948 10943 6 |||||| ND4 
 miR-410-5p  2 12549 12544 6 |||||| ND5 
 miR-410-5p  2 12558 12553 6 |||||| ND5 
 miR-410-5p  2 12862 12857 6 |||||| ND5 
 miR-410-5p  1 13450 13445 6 |||||| ND5 
 miR-410-5p  1 13641 13636 6 |||||| ND5 
 miR-539-5p  2 7287 7281 7 ||||||| COX1 
 miR-539-5p  2 13737 13731 7 ||||||| ND5 
 miR-539-5p  1 6350 6345 6 |||||| COX1 
 miR-539-5p  1 6492 6487 6 |||||| COX1 
 miR-539-5p  2 7196 7191 6 |||||| COX1 
 miR-539-5p  3 9961 9956 6 |||||| COX3 
 miR-539-5p  1 11920 11915 6 |||||| ND4 
 miR-539-5p  1 12095 12090 6 |||||| ND4 
 miR-539-5p  1 12594 12589 6 |||||| ND5 
 miR-539-5p  1 13251 13246 6 |||||| ND5 
 miR-539-5p  1 13905 13898 8 |||||||| ND5 
 miR-542-3p  2 13817 13811 7 ||||||| ND5 
 miR-598-5p  3 5327 5322 6 |||||| ND2 
 miR-598-5p  3 13188 13183 6 |||||| ND5 
 miR-598-5p  1 13941 13936 6 |||||| ND5 
 miR-598-5p  3 14067 14062 6 |||||| ND5 
 miR-652-3p  2 3464 3459 6 |||||| ND1 
 miR-99a-3p  3 6025 6020 6 |||||| COX1 
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Protocols for transfomation 
Rubidium chloride method for preparation of competent E. coli 
(adapted from LTD protocols 2001) 
1. Inoculate 1mL  of E. coli overnight culture into 100mL Psi broth (scale up or down as needed). 
Incubate @37ºC with aeration until A550=0.48 is reached. 
2. Put culture on ice for 15 min. Work in cold room at all times during the preparations of competent 
cells. 
3. Pellet cells in appropriate centrifuge tube 3-5000xg 5 min (~5000rpm in a Sorvall SS-34 rotor). 
4. Discard supernatant and add 0.4volume (i.e. of original volume, here it is 40mL) TfbI, resuspend 
well and put culture on ice 15 min. 
5. Pellet cells as in #3. 
6. Discard supernatant and resuspend in 0.04volume TfbII, and put on ice for 15 min and either use 
immediately or quick freeze at -70ºC for storage. I usually save these in 0.2 to 0.5mL aliquots. Quick 
freeze in ethanol-dry ice bath or liquid nitrogen prior to storage. Thaw on ice just before using in a 
transformation experiment.  
 
Medium and buffers 
 Psi broth (per liter)  Amount 
 Bacto yeast extract   5   g (or from Sigma) 
 Bactro yeast tryptone  20 g (or from Sigma) 
 Magnesium sulfate (7H2O)  5   g (Sigma) 
 pH  7.6 with KOH (10 drops) 
 Autoclave 
 
 TfbI (per 200mL)  Amount Final conc. 
 Potassium acetate  0.588 g 30mM 
  Rubidium chloride  2.42   g 100mM 
  Calcium chloride  0.294 g 10mM 
  Manganese chloride  2.0     g 50mM 
  Glycerol   30mL 15% w/v  
  pH 5.8 with 10% acetic acid * 
  Autoclave 
*The correct pH may be tricky to get accurate. Don’t get the pH too low the solution will precipitate. 
  TfbII (per 100mL)   Amount Final conc. 
  MOPS   0.21 g 10mM 
  Calcium chloride  1.1   g 75mM 
  Rubidium chloride  1.121 g 10mM 
  Glycerol   15mL 15% w/v 
 pH 6.5 with dilute NaOH* 
 Autoclave 
* The correct pH may be tricky to get accurate. Don’t get the pH too high the solution will precipitate. 
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Transformation of chemical competent cells 
1. Thaw competent cells on ice 
2. add DNA to the cells (e.g. 5µl DNA + 50µl cells) 
3. Incubate 30minuttes on ice 
4. Then incubate for 45sec @ 42 degree (water bath) 
5. Put on ice for 2minuttes 
6. Add 900µl LB medium (without antibiotics) 
7. Incubate for 1h @37 degree 
8. Plate different amounts (e.g. 20µl and 200µl) out on a LB-plate containing the appropriate selection 
antibioticum 
9. Grow overnight @37 degree 
10. Colonies formed on the LB-plates indicate successful transformation. 
I usually transform 50L cells with 2-10L of a ligation reaction, and you should get between 108 to 109 
colony forming units/g DNA. With cells prepared with the Rubidium chloride method. 
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Protocols for the care of INS-1e cell culture 
Cell culture of Ins-1 E Takes about 2 weeks to grow when thawed. Use the cells to a max. passage number 
of #105.  
Medium 
RPMI 1640 w. glutamax (500ml) is supplemented with 5ml Penicillin/Streptomycin and 10% FBS (50ml, heat 
inactivated!) and 500µl β-Mercaptaethanol. 
Thawing of frozen cell culture 
1. Prepare medium and a T75 flask under the LAF-bench 
2. Get cells from the nitrogen tank; carry them on ice or dry ice 
3. Gently thaw the vial in warm water or your hand.  
4. Add a small amount fresh medium to the vial, pipet up and down and transfer the cells to the flask 
containing fresh medium. 
Splitting procedure 
1. Remove medium 
2. Wash cells once with PBS (room temp, approx. 10ml for T75) 
3. Add 1ml Trypsine per T75 (T. is in the LTD cell culture fridge as well) 
4. Shake to distribute the trypsine and incubate ~3’ at 37 degree 
5. Add 4ml medium and wash the cells of the surface + pipette up and to down single them 
6. Transfer to 15ml falcon and add another 5ml medium (total vol=10ml) 
7. Centrifuge, RT, 5’, 1000rpm 
8. Remove supernatant and add 10ml medium to the cells 
9. Count the cells using the counter chamber (>50 cells: one square is sufficient…) 
10. Distribute the cells: T75 – 3x10^6 cells, endvolume ~15ml; 6well – 1x10^6/well, endvol 2ml 
Normal time schedule 
Monday (splitting), Wednesday(change medium), Friday (change medium) 
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Protocolls for reporter gene assay 
Transfection of INS-1e cells with lipofectamine 
 
Monday: 
Split INS-1e cells and seed 1.25*105 cells in 250µl of RPMI 1640 glutamax media pr well in a polylysine 
coated 48 well plate. 
Tuesday: 
Prepare DNA-lipofectamine mixes and transfect the INS-1e cells. First prepare the DNA mix, then the 
lipofectamine mix. Drip the lipofectamine mix ontop of the DNA mix and incubate for 20minuttes. While 
incubating change the media of the INS-1e cells to 250µl new  RPMI 1640 glutamax media. After incubation 
add 50µl DNA-lipofectamine mix to each well and incubate the cells for 48hrs. 
DNA mix:  pr. well 
Reporter vector: 600ng 
Normalization vector 50ng 
miRNA mimic  25pmol(if included) 
Optimem media to 25µl  
 
GFP control DNA mix pr. well 
GFP vector  600ng 
Optimem media to 25µl 
 
DNA mix:  pr. well 
Lipofectamine 2000 1µl 
Optimem media 24µl 
  
Thursday: 
After 48hrs the cells can be analysed with the GloMax with the Dual-Light assay, transfection efficiency can 
be monitored as a ratio of GFP positive cells/divided with the total number of cells *100%. 
 
 
Measurement with Dual Light system: 
This requires the Dual-Light® Luciferase & β-Galactosidase Reporter Gene Assay System from 
ThermoFischer scientific – and the name refers to the name of the solutions included. 
HARVESTING OF CELLS: 
1) Withdraw the required amount of Tropix Lysis Solution and add DTT to 0.5 mM.  
Volume needed is 65µL/48well+10% 
2) Wash once with PBS (RT) 
Volume needed is 300µL/48well 
3) Harvesting the cells with the 0.5mM DTT Lysis Solution by adding 65 uL/48 well.  
Distribute the buffer with the pipet tip so that all cells are covered. 
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4) Put the plate (s) on stirrer and let them shake for 5 minutes (no heat). 
 Analyse the extracts or freeze them at -20 ° C for later analysis. 
 
CHEMILUMINECENSE measurement of luciferase: 
1) Warm buffer A and B to rt. and wash the luminometer 
2) prepare buffer A and B 
Add Galacton-plus to buffer B (diluted 1:100) volume needed is 100 ul per sample 
plus 1500 ul. 
Buffer A volume required is needed is 25 ul per sample plus 1500 ul. 
3) Pipette 10 ul cell extract in the measuring plate. 
4) Add buffer A and B to injection system and prime it. 
5) Add 25 ul of buffer A followed by 100µl Buffer B within 10min 
6)  
measure the luciferase activity.  
 
CHEMILUMINECENSE measurement of  galactosidase: 
1) Incubate the samples 30 to 60 minutes at rt. 
2) Add Accelerator II on luminometer, volume needed is 100µl per sample plus 
1500µl. 
3) Wash the luminometer and prime it with Accelerator II. 
4) Mesure galactosidase activity by adding 100 ul Accelarator II by luminometer 
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Protocols for GSIS 
Nucleofection 
 
Preparation: 
For each nucleofection make sure the materials needed are prepared and preheated in the incubator: 
 
Protocol: 
1. Split cells and add a falcon tube with 5ml of RPMI 1640 glutamax media into the incubator. 
2. Spin down 8 x 106 cells for each nucleofection in separate tubes 
 
The following is done for each tube/nucleofection at a time: 
3. Carefully remove the media without disturbing the pellet 
4. Resuspend cells in 100 µl solution V 
5. Add 8 µl of 25µM miRNA mimics. 
6. Mix by up and down 
7. Transfer exactly 100 µl to an AMAXA cuvette 
8. Nucleofect with program T-030 
9. Immediately add 500 µl preheated full media from the preheated falcon tube to the cuvette  
10. Transfer the nucleofected cells back to the falcon tube with preheated media using the specialized 
pipette. 
11. Dispense 1.6million (1ml) of the nucleofected cells into a 3cm plate and 3.2million (2ml) of cells 
into a 6cm plate 
12. Dilute the remaining cells with 6.6ml of media and add  0.4million cells (1ml) per well into eight 
wells of a 24well plate. 
13. Place the well back into the incubator and start from bullet 5 with the next miRNA mimic 
 
GSIS 
 
Media and buffers 
Base media: RPMI 1640 (500ml) is supplemented with 5ml Penicillin/Streptomycin and 10% FBS (50ml, heat 
inactivated!) and 500µl β-Mercaptaethanol. 
KRBH buffer:  123.5mM NaCl, 4.75mM KCl, 1.19mM MgSO4, 1.19mM KH2PO4, 5mM NaHCO3, 10mM HEPES 
(pH7.4). Adjust the pH to 7.4 with NaOH and sterile filter the solution. 
Immediately before use supplement the KRBH buffer to 2.54mM CaCl2 and 0.2% free fatty acid depleted 
bovines serum albumin, using sterile reagents. 
1. 24 hours after nucleofection, the media is changed to basemedia supplemented to 5mM glucose. 
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After 48hours  
1. Extract RNA from the 3cm plate using thermofischer TRIzol reagent – see protocol 
2. Extract protein from the 6cm plate using RIPA buffer – see protocol 
3. Remove old media on the 24well plates and replace with base media supplemented with 3mM 
glucose and allow it to incubate for 3 hrs 
4. While the 3 hours going an aliquot of PBS is added into the incubator and a box of ice and the KRBH 
buffer is added the CaCl2 and BSA. 500µL is needed for each well. Divide the KRBH buffer and 
supplement one half with 3mM glucose and the other half with 20mM glucose. 
5. Remove the media and carefully wash the cells with 1.5mL lukewarm PBS per well. 
6. Add 500µL of the glucose supplemented KRBH buffer to the well with high and low glucose 
conditions respectively. 
7. Wait 2hrs. 
8. Draw 500µl of the supernatant into an eppendorf tube, and centrifuge the eppendorf tube at 500g, 
for 5min @ RT.  
9. Draw 450µl from the centrifuged tube into a new eppedorf tube – this contains the insulin. 
10. Wash the wells with icecold PBS and extract the protein. 
Measurement of the insulin content. 
Rat Insulin Elisa 
Coatning of 96 wells plates: 
Abcam 8522 is diluted 1:1000 in  coatningsbuffer pH 9,8 and added 125µl / well, before Incubated overnight at. 4°C 
wash: 4 x with 1x wash solution 
Secondary Insulin antibody 
PC2005 is diluted 1:1000 and added 125µl / well before Incubated overnight at. 4°C 
wash: 4 x with 1x wash solution 
Antigen-incubation with PO-conjugate: 
Samples are diluted with incubation buffer as needed to measure within the standard curve and 100µl added pr. well 
remember to include a standards 
PO-insulin is diluted 1:10000 with incubationbuffer, and each well added 25µL of the diluted PO 
PC2005 is diluted 1:1000 and added 125µl / well before Incubated overnight at. 4°C 
wash: 4 x with 1x wash solution 
Chromogen development 
Add 125µL TMB pr well and incubate for 30min at RT in the dark 
Add the stop reagent125µL  2M Phosphoricacid/ well 
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Measurement of the plates: 
450nm for the sample and 690nm for the background and is subtracted fom the 450nm. 
Revers transcriptase 
Reverse transcriptase – use the reagent in the Superscript III RT kit from invitrogen.  
1. Mix each sample according to table 
Reagents Concentrations 
H2O To 6.5µl 
RNA sample 
 
100ng 
Primerpool 1µl 
dNTP 10mM 1µl 
 
2. Incubate the samples for 5 min @ 65°C 
3. Incubate in ice for atleast 1 min. 
4. Add µL RT mix to all samples 
5. Mix well and spin down. 
6. Incubate 5min at RT 
7. Incubate in a thermocycler for 45 min @ 50°C followed by 15 min @°C 
8. Add 1µL RNase H to each sample (optional) 
9. Incubate in a thermocycler for 20 min @ 37°C 
10. Spin reactions down and proceed with qPCR or store @ -80°C 
RT mix/sample 
Reagents Concentrations 
5x RT buffer 2µl 
0.1 M DTT 
 
0.5 
RNAse out 0.5µl 
SSIIIRT 1µl 
 
Primer pool: 
Reagents Concentrations 
H2O - 
miR-125a-5p looped primer 
miR-152-3p looped primer 
miR-223-3p looped primer 
TFIIB forward/RT primer 
 
2µM af hver 
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Protocols for cloning 
miRNA reporter gene vectors 
Digestion of pGL4.13 with FseI and XbaI 
Reagents  Volume Concentration 
pGL4.13 (288ng/µL) 17.4µl 5000ng 
H2O  64.1µl - 
FseI (2U/µl)  5µl 2U/µg DNA 
XbaI (10U/µl)  2,5µl 5U/µg DNA 
BSA 100x  1µl 1x 
NEB Buffer 4 10x 10µl 1x 
Digested overnight @ 37°C 
The digested product is loaded on a 1% agarose gel, and run at 80-100V until proper separation Is achieved. 
The backbone is then cut out of the gel with a clean scalpel and the DNA purified. 
The vector backbone will then be ligated in 1:3 molar ratio to the insert prepared from the PCR reactions 
described below  with Roche  rapid  ligation kit – following the sticky end protocol. 
PCR for mutagenesis 
PCR mix: 
Ingredient Concentrations 
H2O - 
HF buffer 5x 1x 
dNTPs 200µM 
Forward Primer  0.5µM 
Reverse Primer  0.5µM 
Template  10ng 
Phusion HF polymerase 2U/µL 2U 
 
Cycling conditions: 
D-loop: 
Primers: 
D-loop forward 
D-loop reverse 
Template: 
HEK293 DNA 
 Temperature Time Cycles 
98°C 30s 1 
98°C 10s 
10 63°C 20s 
72°C 20s 
72°C 600s 1 
4°C ∞ 1 
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Isoleucine change, initial PCR: 
 
 
Isoleucine change second PCR: 
 
Reaction1 
Primers: 
Forward – universal and 
Reverse – isoleucine 
Template: 
pGL4.13 
 
Reaction 2 
Primers: 
Reverse – universal and 
Forward – isoleucine 
Template: 
pGL4.13 
 
 Temperature Time Cycles 
98°C 30s 1 
98°C 10s 
10 
72°C 
Δ-1°C/ cycle 
20s 
72°C 20s 
98°C 10s 
15 62°C 20s 
72°C 20s 
72°C 600s 1 
4°C ∞ 1 
Primers: 
Forward – universal 
Reverse – universal 
 
Template: 
Product from reaction 1 and 2 
 
 Temperature Time Cycles 
98°C 30s 1 
98°C 10s 
10 55°C 20s 
72°C 20s 
72°C 600s 1 
4°C ∞ 1 
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Stop codon change: 
Reaction1 
Primers: 
Forward – universal and 
Reverse – Trp to stop 
Template: 
Isoleucine changed pGL4.13 
 
Reaction 2 
Primers: 
Reverse – universal and 
Forward – Trp to stop 
Template: 
Isoleucine changed pGL4.13 
 Temperature Time Cycles 
98°C 30s 1 
98°C 10s 
10 
72°C 
Δ-1°C/ cycle 
20s 
72°C 20s 
98°C 10s 
15 62°C 20s 
72°C 20s 
72°C 600s 1 
4°C ∞ 1 
 
Trp to stop second PCR: 
Primers: 
Forward – universal 
Reverse – universal 
 
Template: 
Product from Trp to stop reaction 1 and 2 
 
 Temperature Time Cycles 
98°C 30s 1 
98°C 10s 
10 55°C 20s 
72°C 20s 
72°C 600s 1 
4°C ∞ 1 
 
 
 
